Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 4264  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission




 
 Table of Contents  
REVIEW ARTICLE
Year : 2014  |  Volume : 6  |  Issue : 3  |  Page : 139-150  

Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues


1 Department of Pharmaceutics, J. C. D. M. College of Pharmacy, Sirsa, Haryana, India
2 Department of Pharmaceutical Chemistry, J. C. D. M. College of Pharmacy, Sirsa, Haryana, India

Date of Submission05-Sep-2013
Date of Decision29-Sep-2013
Date of Acceptance14-Nov-2013
Date of Web Publication24-Jun-2014

Correspondence Address:
Deepti Pandita
Department of Pharmaceutics, J. C. D. M. College of Pharmacy, Sirsa, Haryana
India
Login to access the Email id

Source of Support: The Science and Engineering Research Board, Department of Science and Technology, Government of India is acknowledged for funding through the project SR/FT/LS.145/2011, Conflict of Interest: None


DOI: 10.4103/0975-7406.130965

Rights and Permissions
   Abstract 

Dendrimers are the emerging polymeric architectures that are known for their defined structures, versatility in drug delivery and high functionality whose properties resemble with biomolecules. These nanostructured macromolecules have shown their potential abilities in entrapping and/or conjugating the high molecular weight hydrophilic/hydrophobic entities by host-guest interactions and covalent bonding (prodrug approach) respectively. Moreover, high ratio of surface groups to molecular volume has made them a promising synthetic vector for gene delivery. Owing to these properties dendrimers have fascinated the researchers in the development of new drug carriers and they have been implicated in many therapeutic and biomedical applications. Despite of their extensive applications, their use in biological systems is limited due to toxicity issues associated with them. Considering this, the present review has focused on the different strategies of their synthesis, drug delivery and targeting, gene delivery and other biomedical applications, interactions involved in formation of drug-dendrimer complex along with characterization techniques employed for their evaluation, toxicity problems and associated approaches to alleviate their inherent toxicity.

Keywords: Dendrimer, drug targeting, drug-dendrimer interactions, gene delivery, polyamidoamine


How to cite this article:
Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J Pharm Bioall Sci 2014;6:139-50

How to cite this URL:
Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J Pharm Bioall Sci [serial online] 2014 [cited 2022 Dec 7];6:139-50. Available from: https://www.jpbsonline.org/text.asp?2014/6/3/139/130965

Several therapeutic agents suffer from various limitations like low aqueous solubility and short half-life. Therefore it is necessary to design a delivery system, which can deliver a drug efficiently. Conventional drug delivery systems are useful to some extent in overcoming these issues, but they have failed to prove their effectiveness in delivering many drugs. Nanoparticle assisted drug delivery provides a platform to modify the basic properties of drug molecules viz. solubility, half-life, biocompatibility and its release characteristics. Several nanoparticle based therapeutic products have been launched in the market while some are under clinical and preclinical trials. [1] Liposomes and polymeric-drug conjugates hold the maximum share of it. For instance, Doxil® (doxorubicin HCl liposome injection) [2] and Abraxane® (paclitaxel protein-bound particles for injectable suspension) [3] are administered as first-line treatments in various cancer types. The stability and toxicity issues associated with these technologies has remained a matter of concern untilnow. [1] The traditional linear polymers viz. polyethylene glycol (PEG), polyglutamic acid, polysaccharide, poly (allylamine hydrochloride) and N-(2-hydroxypropyl) methylacrylamide have been reviewed as drug delivery vehicles and accepted for clinical use, [4] but these linear polymers have poorly defined chemical structures. In this scenario, many attempts have been made to alleviate the problems associated with them. Moreover, the considerable interest of scientists in delivering therapeutic, targeting and diagnostic agents together in a single system has led to the usage of the novel class of nanoparticles as multifunctional platforms. The introduction of highly branched, well-defined molecular architectural polymers, i.e. Dendrimers, firstly in 1978 by Vogtle has provided a novel and one of the efficient nanotechnology platforms for drug delivery. [5]

Dendrimers are three-dimensional, immensely branched, well-organized nanoscopic macromolecules (typically 5000-500,000 g/mol), possess low polydispersity index and have displayed an essential role in the emerging field of nanomedicine. The name has actually derived from the Greek word "dendron" meaning "tree," which indicates their unique tree-like branching architecture. They are characterized by layers between each cascade point popularly known as "Generations." The complete architecture can be distinguished into the inner core moiety followed by radially attached generations that possess chemical functional groups at the exterior terminal surface [Figure 1]. [6],[7] With the increase in generations, the molecular size and terminal surface groups amplifies that offer wide potential for multiple interactions and hence termed as highly functional [Figure 2]. This multivalency has subjected to the formation of various host-guest complexes that offer wide applications. [Table 1] highlights the different commercialized dendrimers and dendrimer-based products. The present review highlights the different strategies for their synthesis, recent updates in drug delivery applications, the specific interactions playing a significant role in entrapment/conjugation of drugs, the characterization techniques of dendrimers and their drug conjugates, several aspects of dendrimers like toxicity issues and other applications.
Table 1: List of commercially available dendrimers and dendrimer-based products

Click here to view
Figure 1: Schematic representation of dendrimer components. Reproduced with permission from ref.,[7] Copyright 2005, Elsevier

Click here to view
Figure 2: Dendrimers as multifunctional nanoplatforms

Click here to view



   Technology Platforms Top


The advances and innovations of polymer science and architectural chemistry have resulted in the development of dendrimers as multifunctional highly branched polymeric systems. Various dendritic platforms such as polyamidoamine (PAMAM), poly (propylene imine) (PPI), poly-L-lysine, melamine, poly (etherhydroxylamine) (PEHAM), poly (esteramine) (PEA) and polyglycerol have been synthesized and explored as drug delivery vehicles. [7],[18] The synthesis of dendrimers can be traced back to 1980's when D. Tomalia used "divergent methodology" to synthesize them. The strategy involves the coupling of monomeric molecules that possesses reactive and protective groups with the multifunctional core moiety which leads to stepwise addition of generations around the core followed by removal of protecting groups. PAMAM-NH 2 dendrimers were firstly synthesized by coupling N-(2-aminoethyl) acryl amide monomers to an ammonia core and today they are the most systematically synthesized and commercialized family of dendrimers using this methodology. This method offers an advantage of producing modified dendrimers by changing the end groups and in turn their physicochemical properties can be altered as per the required application. Although, this approach suffers from limitation of structural defects due to incomplete reaction of groups which can be trounced by the excessive addition of monomeric units. [6],[19]

Another approach "convergent methodology" of synthesizing dendrimers was pioneered by Hawker and Frechet in 1990's. This strategy refers to the inward growth by gradually assembling surface units with reactive monomers. This approach produces more homogenous and prιcised molecular weight products. The deactive side products produced during reactions gets easily separated by purification, but this becomes harder in higher generations due to similarity in products and reactants. The convergent methodology suffers from one major limitation that it gives low yield in the synthesis of large structures and hence is suitable for production of only lower generation dendrimers. [20] These synthesis methodologies are presented in [Figure 3].
Figure 3: Schematic representation of dendrimer synthesis by (a) Divergent and (b) Convergent methodologies

Click here to view


Other approaches that have been employed for dendrimer synthesis include "Hypercore and branched monomers"; "Double exponential"; "Lego chemistry" and "Click chemistry." The first approach involves the pre-assembly of oligomeric species to accelerate the production of dendrimers in few steps with high yield, [21] whereas the double exponential approach follows the production of monomer unit for both divergent and convergent growth from a single functionalized group. The produced monomer units are allowed to react, which produces an orthogonally protected trimer that is grown further. Advantages of this method include accelerated synthesis of dendrimers and this method can be applied to both convergent and divergent method. [21] Lego chemistry approach employed by Tomalia and Svenson involves the production of phosphorus dendrimers by utilizing highly functionalized core and branched monomers. Several changes have been made to the basic scheme of synthesis and more refined schemes are being developed, which involves the multiplication of terminal surface groups from 48 to 250 in one step. [22] The same authors used click chemistry method in successful production of triazole dendrimers using Cu (I)-catalyzed click chemistry reactions. Again, this methodology is involved in hasten synthesis of dendrimers by divergent approach with high purity and excellent yield. This technique involves the reaction of two different monomeric units of complimentary functionalities that render spontaneous synthesis by avoiding the use of activating agents/protecting groups and reducing the number of steps. [19] More future work is needed to find out the cost-effective synthesis strategies for successful commercialization of this technology.


   Dendrimers for Drug Delivery and Targeting Top


The precise control over the distribution of drugs is highly valuable to abolish the typical drawbacks of traditional medicine. Thus, a drug delivery system should be designed to attain the site-specific delivery preferentially. In recent years, improved pharmacokinetics, biodistribution and controlled release of the drug to the specific targeted site has been achieved with polymer based drug delivery. [23] Unlike traditional polymers, dendrimers have received considerable attention in biological applications due to their high water solubility, [24] biocompatibility, [25] polyvalency [12] and precise molecular weight. [26] These features make them an ideal carrier for drug delivery and targeting applications. For investigating dendrimers as drug delivery vehicles, their biopermeability across the biological membranes should be considered. A study by Kitchens et al. reviewed the cationic PAMAM-NH 2 (G0-G4) dendrimers and evaluated its permeability across Caco-2 cell monolayers as a function of dendrimer generation, concentration and incubation time, for oral drug delivery. Various parameters viz. transepithelial electrical resistance, 14 C-mannitol permeability and leakage of lactate dehydrogenase enzyme were studied and it was suggested that these amine terminated PAMAM dendrimers could cross the biological membranes possibly by paracellular and endocytosis pathways. [27] Moreover, by optimizing the size and surface charge, these dendritic platforms can be developed into oral delivery systems.

Different categories of drugs that have been incorporated in these versatile nanoscopic carriers as summarized in [Table 2]. Recently, a dendrimer based prodrug has been developed for paclitaxel (P-gp efflux substrate) that has focused on enhancement of permeability and transportation of drug across cellular barriers. The highly functional lauryl-modified G3 PAMAM dendrimer-paclitaxel conjugates demonstrated good stability under physiological conditions and 12-fold greater permeability across Caco-2 cell and porcine brain endothelial cells monolayers than paclitaxel alone. Finally, the authors concluded that surface-modified G3 PAMAM dendrimers could be considered as potential nanocarriers for poorly water-soluble P-gp efflux transporter drugs. [32] Earlier Ooya et al. reported 400 times increase in the solubility of paclitaxel when incorporated in polyglycerol dendrimers. [30]
Table 2: Different therapeutic moieties studied using dendrimer platform

Click here to view


The targeted delivery of chemotherapeutics is essential to reduce the side effects significantly associated with conventional therapy, where healthy tissues such as liver, spleen, kidneys and bone marrow can accumulate the toxic levels of drug. The site specific delivery of the drug could be achieved by surface modification of dendrimers employing various targeting moieties such as folic acid (FA), peptides, monoclonal antibodies and sugar groups. [56] Several successful active and passive targeting attempts were accomplished by engineering the branching units and surface groups of dendrimers. Patri et al. conjugated FA to G5 PAMAM dendrimer for the targeted delivery of methotrexate and observed receptor mediated drug delivery that demonstrated high specificity for KB cells overexpressing folate receptors and showed slower drug release. [35] The authors further conjugated the PhiPhiLux G1 D2, an apoptotic sensor to FA attached PAMAM dendrimers which showed 5 fold enhanced fluorescence, attributed to successful delivery of drug with cell-killing efficacy. [57] FA conjugated G5 PAMAM dendrimers for the targeted delivery of 2-methoxyestradiol to cancer cells, as confirmed by MTT assay, were recently reported. [58] Sideratou et al. prepared folate functionalized PEG coated nanocarrier based on fourth generation diaminobutane PPI dendrimers for targeted delivery of etoposide. [59] The encapsulation of the drug inside the dendrimeric scaffold resulted in enhanced solubility of etoposide, further the in vitro release of encapsulated drug from these functionalized dendrimers was found to be sustained and comparable to the non-functionalized dendrimers. These folate PEGylated dendrimers exhibited specificity for folate receptor with low toxicity. Furthermore, successful conjugation of FA to fifth generation PPI dendrimers was explored and its potential in targeted delivery of an anticancer drug doxorubicin was investigated. The results revealed that FA conjugated dendrimers displayed higher cell uptake in MCF-7 cancer cell lines and significantly reduced the toxicity. [60]

Further, Patri et al. group explored the usage of monoclonal antibodies for site-specific delivery by conjugating prostate specific membrane antigen (PSMA) J591, an anti-PSMA to G5 PAMAM dendrimers that showed targeted delivery in all prostate and non-prostate tumors. [61] Methotrexate bound to G5 PAMAM conjugate containing cetuximab [62] or anti- human epidermal growth factor receptor-2 [63] monoclonal antibodies have demonstrated their potential in tumor targeted drug delivery.

Using glycosylated dendrimers, terminally modified with sugar moieties is another strategy for targeting applications. In a study, colchicine was successfully conjugated with glycodendrimer that showed selective 20-100 times inhibition of HeLa cells than healthy cells. [64] A study done by Ciolkowski et al. examined the influence of dendrimers' surface modification on the strength of interaction with proteins. This study was carried out using PPI G4 and G3.5 PAMAM dendrimers as a drug carrier and hen egg white lysozyme as a model protein. As shown by differential scanning calorimetry (DSC) and circular dichroism studies the increasing maltose modification on the surface of PPI dendrimers resulted in diminishing ability of dendrimer to interact with lysozyme because the surface charge of complexes turned neutral from cationic. [65] In addition, a comparably strong influence exerted on lysozyme by positively charged PPI dendrimer and negatively charged PAMAM dendrimer.


   Dendrimers for Gene Delivery Top


Gene transfer is an invaluable experimental tool that involves the introduction of new genetic material to host for treatment of diseases. Various vectors and physical methods are reported for in vivo delivery of therapeutic nucleic acids. Commonly two approaches viz. viral and non-viral based are being used to facilitate the transfer of genetic material successfully to target cells. Although viral carriers can achieve rapid transfection, but immunological and oncologic adverse effects associated with these vectors has remained a topic of concern. Non-viral gene delivery vectors offer the usage of natural/synthetic molecules or physical forces to transfer genetic material to targeted cells. Several advantages such as ease of fabrication, targeting ability, potential for repeat administration and low immune response have led to the usage of non-viral vectors preferably for gene therapy. Santos et al. extensively reviewed various physical and chemical methods for non-viral gene delivery, dendrimers based vectors and their applications in tissue engineering and regeneration. [66] Among various commercially available dendrimers, PAMAM dendrimers have received the most attention as potential non-viral gene delivery agents due to their cationic nature which enables deoxyribonucleic acid (DNA) binding at physiological pH. [67] Pandita et al. prepared dendrimer based gene delivery vectors taking advantage of the cationic nature and the "proton-sponge" effect of these dendrimers. Arginine-glycine-aspartic (RGD) nanoclusters were formed by conjugation of G5 and G6 PAMAM dendrimers with a varying number of peptides containing the RGD motif, in view of its targeting capabilities [Figure 4]a. Authors reported that the system wherein G6 PAMAM dendrimer was conjugated to eight peptide arms (RGD8-G6) enhanced the gene expression in mesenchymal stem cells and presented a 2-fold higher bone morphogenetic protein-2 expression in comparison to the G6 native dendrimer. [68] Various published literature suggests that functionalized dendrimers are much less toxic than the native dendrimers. Same group synthesized a new family of gene delivery vectors consisting of G5 PAMAM dendrimer core randomly linked to hydrophobic chains (with varying chain length and numbers) [Figure 4]b. In vitro studies revealed a remarkable capacity of these vectors for internalizing pDNA with very low levels of cytotoxicity, being this effect positively correlated with the CH 2 content present in the hydrophobic moiety. The results demonstrated that vectors containing the smallest hydrophobic chains (La1-G5 and La2-G5 functionalized dendrimers) showed the higher gene expression efficiency. [69] Further, functionalized PAMAM dendrimers exhibited low cytotoxicity and receptor-mediated gene delivery into mesenchymal stem cells and transfection efficiencies superior to those presented by native dendrimers and by partially degraded dendrimers. [70] A low affinity mesenchymal stem cells binding peptide and a high affinity mesenchymal stem cells binding peptide were conjugated with PAMAM dendrimers in the studies, providing for a mechanism of cell specific recognition [Figure 4]c.
Figure 4: Schematic representation of polyamidoamine dendrimer-based gene delivery vectors. (a) Schematic illustration of the synthesis of dendrimer/RGD conjugates (pathway A + B) and of the indirect estimation of the number of pyridyldithiol (PDP) units per dendrimer by spectrophotometry (pathway A + C). Reproduced with permission from ref.,[68] Copyright 2011, American Chemical Society. (b) Strategy of synthesis followed in dendrimer surface functionalization with alkyl chains (activation of the fatty acid + conjugation reaction). Reproduced with permission from ref.,[69] Copyright 2010, Elsevier. (c) The two-step reaction for the synthesis of peptide-functionalized G5 PAMAM dendrimers (pathway A + B), and for indirect estimation of the number of peptide units by spectrophotometry (pathway A + C). Reproduced with permission from ref.,[70] Copyright 2010, American Chemical Society

Click here to view


The antigen-presenting cells specific delivery of DNA by peptide functionalized G5 PAMAM dendrimers is also described. In vivo study on mice suggested that functionalized PAMAM dendrimer complexes can be used for effective targeting to antigen-presenting cells so as to achieve high transfection efficiency. [71] More recently, Bai et al. investigated the efficacy of arginine-modified PAMAM dendrimers in delivering human interferon beta gene on a xenograft brain tumor mice model. The study revealed that functionalized dendrimers reduce the tumor size effectively, which confirms the tumor targeting potential of peptide functionalized dendrimers. [72]

Recently, Shan et al. reported a novel non-viral gene delivery vector based on dendrimers-entrapped gold nanoparticles synthesized using amine-terminated G5. NH 2 dendrimers as templates with different Au atom/dendrimer molar ratios, which showed higher transfection efficiency than that of dendrimers without Au nanoparticles entrapped. [73] Ferenc et al. investigated dendriplexes formed by short interfering RNA (siRNA) and cationic phosphorus dendrimers. The siRNA conjugated dendriplexes showed good stability as shown by laser doppler electrophoresis and circular dichroism spectra. [74] Previously, Drzewinska et al. functionalized PPI dendrimers by maltose or maltotriose conjugation and interacted it with anti-human immunodeficiency virus antisense oligonucleotides to form dendriplexes. These carbohydrate-modified PPI G4 dendrimers protected oligonucleotides from nucleolytic degradation at neutral pH but in an acidic environment, the protective effect of these dendrimers was weaker. [75] A high molecular weight bioreducable polymer was synthesized by Nam et al. for gene delivery by incorporating arginine-grafted poly (disulfide amine) into the PAMAM dendrimer. The resultant polyplexes significantly enhanced the cellular uptake and were less susceptible to reducing agents, ensuing superior transfection efficiency. [76]


   Drug-Dendrimer Interactions Top


Dendrimers offer several mechanisms of interactions with different classes of drugs. The different types of drug-dendrimer interactions proposed for drug delivery are presented in [Figure 5]. [77] Broadly these interactions can be categorized under two categories viz. physical and chemical bonding.
Figure 5: Different types of drug-dendrimer interactions. The darkened oval represents an active substance. Reproduced with permission from ref.,[77] Copyright 2002, Elsevier

Click here to view


Physical bonding

Incorporation of small organic molecules may be a result of non-bonding interactions with specific groups within dendrimer, i.e. just physical entrapment. Dendrimers can be used as dendritic boxes and unimolecular micelles (dendrimer-drug networks) for the incorporation of hydrophobic/hydrophilic molecules by host guest interactions inside their empty cavities (nanoscale containers) present around core. [78],[79] Jansen et al. were the first to entrap the rose bengal dye molecules in PPI dendrimers by using tert-butyloxycarbonyl (t-Boc) groups and led to the production of stable dendritic box that possess the bulky amino groups on the dendrimer surface. [80] The dendritic unimolecular micelles contain the hydrophobic cores surrounded by hydrophilic shells and they offer an advantage over conventional polymeric micelles such that the micellar structure is maintained at all the concentrations because the hydrophobic segments are covalently connected.

Chemical bonding

Alternatively, the exploitation of well-defined multivalent aspect of dendrimers allows the attachment of drug molecules to its periphery that result in complex formation. The resultant complexes are formed either due to the electrostatic interactions between the drug and dendrimer or conjugation of the drug to dendrimer molecule. Through electrostatic interactions, various ionizable drugs form complexes with the large number of ionizable terminal surface groups of dendrimers. In PAMAM dendrimers, both primary amine and tertiary amine groups present on the surface and within the core respectively are titrable and has pKa values of 10.7 and 6.5 respectively. [81] Hence, they possess the ionizable groups terminally as well as within their core and thus offer potential sites for drug interactions. Many of the drugs such as ibuprofen, [82] piroxicam, [83] indomethacin, [84] benzoic acid [85] have shown to form stable complexes through electrostatic interactions.

Moreover, the drugs can be covalently conjugated to dendrimers through some spacers that may include PEG, p-amino benzoic acid, p-amino hippuric acid and lauryl chains etc., or biodegradable linkages such as amide or ester bonds. This prodrug approach has been found to increase the stability of drugs and has affected their release kinetics significantly. Several researchers have successfully conjugated penicillin V, [86] venlafaxine, [87] 5-aminosalicylic acid, [88] naproxen, [50] propranolol [49] with PAMAM dendrimers. The results have shown the enhanced solubility and controlled release of drugs from these complexes in comparison to the pure drug. Apart from these, many anticancer drugs viz. cisplatin, [89] doxorubicin, [37] epirubicin, [90] methotrexate [24] and paclitaxel [33] have also been conjugated and used for drug targeting. For example, epirubicin prodrug was developed by conjugating it with PEG dendrimers containing aminoadipic acid as branching molecules. These conjugates exhibited increased blood residence time and showed improved therapeutic action. The study revealed that PEG dendrimers increased the stability of bound drug toward chemical degradation and hence can be used potentially in the development of prodrugs of large molecules. [90]


   Physicochemical Characterization of Dendrimers Top


Various analytical techniques have been reported in literature to analyze the physicochemical parameters of dendrimers. It includes spectroscopic, dynamic light scattering (DLS), microscopic, chromatographic, rheological, calorimetric and electrophoretic characterization: Nuclear magnetic resonance (NMR), infrared, ultraviolet (UV)-Visible, fluorescence and mass spectroscopy; small angle X-ray scattering, small angle neutron scattering, laser light scattering; atomic force microscopy (AFM), transmission electron microscopy (TEM); size exclusion chromatography, high performance liquid chromatography (HPLC); DSC, temperature modulated calorimetry and dielectric spectroscopy; Polyacrylamide gel electrophoresis (PAGE) and capillary electrophoresis [Figure 6]. [91],[92] All these dendrimer characterization techniques can also be used to study the dendrimer-drug conjugates/complexes. Encapsulation of drug molecules or nanoparticles by dendrimers can be characterized by TEM, UV-Visible and Fourier transform infrared spectroscopy. Moreover, NMR and mass spectroscopic techniques are used to study the nature of complexes. Huang et al. characterized the silybin-PAMAM complexes by NMR and HPLC methods. Chemical shifts of methylene protons of the G2 dendrimers were determined by NMR spectroscopy which apparently was changed with the addition of silybin. [93] The downfield chemical shift in the outermost layer of the G2 dendrimer and the interior methylene protons confirmed the electrostatic interactions between the amine functional groups of the dendrimer and the phenolic hydroxyl groups of silybin; and the encapsulation of silybin molecules by hydrophobic interactions, respectively. HPLC method was used to determine the solubility of silybin and plasma drug concentration of silybin.
Figure 6: Various analytical techniques employed for the physicochemical characterization of dendrimers

Click here to view


The shape and size of paclitaxel solubilized micelles of a linear-dendritic copolymer (BE-PAMAM), formed by conjugating the poly (butylene oxide) (B)-poly (ethylene oxide) (E) block copolymer B16E42(BE) with a G2 PAMAM dendrimer were examined by DLS and cryo-TEM. The studies indicated that spherical micelles got transformed to worm-like micelles of the BE copolymer as a result of encapsulation of paclitaxel molecules. [33] Morilla et al. explored the potential of different generations of PAMAM dendrimers (G4, G5, G6 and G7) to deliver siRNA. [94] The formed complexes were investigated for three variables: The ionic strength of the medium (with or without 150 mM NaCl), G4, G5, G6 and G7 dendrimer generations and N/P ratio, i.e. nitrogen amines in PAMAM/phosphate in siRNA. Various analytical techniques viz. PAGE, DLS, TEM and AFM were used to characterize these variables. PAGE study revealed that in order to complexate the whole available siRNA molecules, a minimum N/P ratio of 5 (for G4, G5) and 10 (for G6, G7), was required. The sizes obtained using DLS, TEM and AFM provided the inverse relationship between size of the formed complex and its binding affinity; and also between the size of the complex and ionic strength of preparation media. Finally, the measured zeta potential of small siRNA PAMAM dendrimer complex was found to reduce from + 25 mV to 0, when drops of sodium chloride were added to the medium due to the formation of larger complexes or even aggregates. The results together indicated that ionic strength of the media was the main determinant of the size of siRNA-dendrimer complex and responsible for the inhibition of enhanced green fluorescent protein expression (silencing activity).

Recently, PAMAM and PPI dendrimers were synthesized by introducing 1,3 propane sultone in tertiary amine of these dendrimers and 1 H NMR studies were performed to calculate their degrees of acetylation and interior-functionalization. The spectrum obtained using correlation spectroscopy revealed J-coupled protons (geminal or vicinal protons) via cross-correlation peaks off the diagonal, which was further used to confirm the structure of the synthesized dendrimers. Further, 1 H- 1 H nuclear overhauser effect spectroscopy (NOESY) was used to characterize the inclusion structure of the synthesized dendrimer and methotrexate sodium complexes that mainly revealed the spatial conformation of dendrimer/drug complexes. The presence of nuclear overhauser effect signals between guest protons and dendrimer interior protons in a 1 H- 1 H NOESY spectrum suggested the encapsulation of the guest molecules within the pockets of dendrimers. [95]


   Toxicity Issues Top


It is well-known that cationic macromolecules interact with negative biological membranes that result in their destabilization and cause cell lysis. [96],[97] The nanosized particles like dendrimers have the ability to interact with nanometric cellular components such as cell membrane, cell organelles and proteins. [98] Similar to macromolecules, dendrimers with cationic surface groups tend to interact with lipid bilayer, increases the permeability and decreases the integrity of biological membrane. The mechanism involved is the leakage of cyotosolic proteins such as luciferase and lactate dehydrogenase, on interaction of dendrimers with the cell membrane that finally causes its disruption and cell lysis. [99],[100] Typical representatives of this class of carriers are PAMAM-(Starburst™), PPI and polylysine-dendrimers. Among them, PAMAM dendrimers are shown to cause concentration and generation dependent cytotoxicity and hemolysis. [99],[101] In an article in 2003, Jevprasesphant et al., investigated the cytotoxicity of PAMAM dendrimers using Caco-2 cells and concluded that anionic or half generation dendrimers show significantly low toxicity in comparison to their respective cationic family. [102] Further, the in vitro cytotoxicity of cationic melamine dendrimers having surface groups such as amine, guanidine, carboxylate, sulfonate or phosphonate were reported and it was concluded that cationic dendrimers were much more cytotoxic than anionic or PEGylated dendrimers. [99] In a study, membrane disruption and loss of Caco-2 microvilli was reported when the cells were treated with 0.1 mM or higher concentration of G4-NH 2 , whereas the cells remained unaffected when treated with G3.5-COOH at the same concentration. [103] Extensive in vitro studies have been performed to assess the toxicity of various modified or native dendrimers on different cell lines. Few scientists also report the essential in vivo toxicity of dendrimers. According to the very first in vivo toxicological study, dose of 10 mg/kg appeared to be non-toxic up to fifth generation of PAMAM dendrimers, when G3, G5 and G7 generations were injected into mice and all the tested generations were found to be non-immunogenic. [104],[105] Recently, Jones et al. performed nano-toxicological studies on amine-terminated PAMAM dendrimers that revealed that intravenous administration was lethal to mice and caused disseminated intravascular coagulation-like condition. Using flow cytometry and microscopic analysis it was demonstrated that cationic fluorescein isothiocyanate labeled G7 PAMAM dendrimers caused platelet disruption, whereas neutral (hydroxyl terminated) and anionic (carboxyl terminated) PAMAM dendrimers did not alter platelet morphology or their function. [106] This recent study is in consistent with the previous studies and justifies that the anionic dendrimers are non-toxic in comparison to cationic ones. Tathagata and co-workers also investigated the toxicity profile of the fifth generation PPI dendrimers and some of its surface engineered derivatives. Functionalization with t-Boc, mannose and tuftsin led to the drastic reduction in the toxicity of PPI, this was attributed to the masking of primary amino groups responsible for the positive charge and thus the associated toxicity. Both PPI and surface engineered derivatives did not show any evidence of immunogenicity. Finally, it was concluded from these observations that functionalization of dendrimers leads to the drastic reduction of toxicity and increased biocompatibility. [107]

The oral acute toxicity study on PAMAM dendrimers in immune competent CD-1 mice was done taking size and charge of dendrimers in consideration. The results revealed that cationic dendrimers caused more toxicity than their anionic counterparts. Maximum tolerated doses of dendrimers was determined by a dose escalation study and it was concluded that the dendrimers were safe for oral administration except for G7-NH 2 and G7-OH, which exhibited signs of toxicity at relatively low dosage. [108] In general, two approaches are being reviewed to overcome the in vitro toxicity issues of dendrimer based nanosystems. Either biocompatible/biodegradable dendrimers viz. polyether, polyester or polyether-imine, polyether-copolyester, phosphate, citric acid, melamine, peptide or triazine dendrimers can be synthesized or the peripheral positively charged groups can be masked by acetylation and PEGylation. Moreover, the surface groups can be functionalized with carbohydrate, amino acid, antibody and FA that abates the overall positive charge and further the toxic effect of primary amines/imines. [109] Hence, it can be concluded that neutral and anionic dendrimers do not interact with biological membranes and are mostly compatible for implied clinical relevance.


   Other Applications Top


The versatility of dendrimers also explains their importance in photodynamic therapy (PDT), boron neutron capture therapy and bioimaging applications.

Dendrimers in PDT

PDT refers to treatment of tumor cells by photosensitizers that on irradiation of light of appropriate wavelength pass their excess energy to nearby molecular oxygen to form reactive oxygen species such as singlet oxygen and free radicals which are toxic to cells and tissues. Dendrimers have been used as promising carriers for improved delivery of 5-aminolevulinic acid (a natural precursor of photosensitizer protoporphyrin 1X) that increases the accumulation of porphyrin in cells, which further results in toxicity. [110],[111],[112] Recently, polymeric micelles encapsulating dendrimer phthalocyanine have been developed as a photosensitizer formulation for enhanced photodynamic effect. [113]

More recently, G3 PAMAM grafted porous hollow silica nanoparticles (PHSNPs) were successfully fabricated as photosensitive drug carriers for PDT. The attachment of gluconic acid (GA) to this system was thereafter followed, for surface charge tuning. PAMAM-functionalized outer layer with a large number of amino groups provided high loading amount of aluminum phthalocyanine tetrasulfonate (AlPcS4), its retarded premature release and effective release to target tissue. The study demonstrated that irradiation of the AlPcS4 entrapped GA-G3-PHSNPs with light resulted in efficient generation of singlet oxygen that produced significant damage to tumor cells and suggested as effective photosensitizer formulation for PDT applications. [114]

Dendrimers in boron neutron capture therapy

Boron therapy is concerned with the treatment of cancers that is based on Boron capture reaction. [115] The applicability of PAMAM dendrimers in investigating intratumoral delivery of agents for neutron capture therapy is remarkable in biomedical science. In a study by Wu et al. functionalized G5 PAMAM dendrimers and conjugated cetuximab specific to EGF receptor to starburst dendrimers that carried around 1100 boron atoms. The in vivo results revealed that accumulation of conjugates were 10 times higher in brain tumor tissues in comparison to healthy brain tissues. This study was first to demonstrate the efficacy of a boronated monoclonal antibody for boron neutron capture therapy of an intracerebral glioma. [116] Dendrimer based boron neutron capture therapy in combination with EGF receptor targeting moieties can enhance the boron uptake in tumor tissues. [117]

Dendrimers as imaging agents

Gadolinium (III) (Gd) the paramagnetic contrast agent for magnetic resonance imaging has been successfully complexed with PAMAM dendrimers over the last decades for visualizing both tumor vasculature and lymphatic involvement. [118],[119] Recently, a tumor targeting biodegradable contrast agent has been developed from Gd chelates and PEG conjugated polyester dendrimer which contains FA at the distal end. This dendrimer conjugate contrasting agent has shown to produce enhanced contrast than commercially available product Magnevist® . Furthermore, it's retention in all the organs was low resulting in reduction of Gd induced toxicity. Thus, these positive outcomes, i.e. enhanced magnetic resonance imaging contrast and low Gd retention makes this dendrimer based biodegradable carrier a promising imaging agent. [120]

Outlook

Last decade has witnessed the amplified growth of usage of dendrimers in biological systems. The exclusive properties viz. well-defined structure, polyvalent character and monodispersity make them effective nanosystems for drug delivery applications. The current review has emphasized on the considerable opportunities that dendrimers offer in resolving fundamental issues of solubility, drug delivery and targeting of drug molecules. In spite of this, their use is constrained due to their high manufacturing cost and further they are not subjected to GRAS status due to the inherent toxicity issues associated with them. As highlighted in the present work, many attempts have been made to resolve the problems pertaining to safety, toxicity and efficacy of dendrimers and more research is going on to develop the functionalized moieties pertaining to its high potential as a nanocarrier. Besides drug delivery, dendrimers have been found to have a great emphasis in gene delivery, boron neutron capture therapy, PDT and as magnetic resonance imaging contrast agents. The use of dendrimers in the clinic has still not reached the success of linear polymers and several applications remain to be explored for its industrial as well as biomedical applications. With improved synthesis, further understandings of their unique characteristics and recognition of new applications, dendrimers will become promising candidates for further exploitation in drug discovery and clinical applications.


   Acknowledgement Top


The authors would like to thank the Science and Engineering Research Board, Department of Science and Technology, Government of India for funding through the project SR/FT/LS-145/2011.

 
   References Top

1.Hu CM, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 2010;1:323-34.  Back to cited text no. 1
    
2.Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-51.  Back to cited text no. 2
    
3.Harries M, Ellis P, Harper P. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J Clin Oncol 2005;23:7768-71.  Back to cited text no. 3
    
4.Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56:1649-59.  Back to cited text no. 4
    
5.Buhleier E, Wehner W, VÖGtle F. "Cascade"- and "nonskid-chain-like" syntheses of molecular cavity topologies. Synthesis1978;2:155-8.  Back to cited text no. 5
    
6.Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, et al. A new class of polymers: Starburst-dendritic macromolecules. Polym J 1985;17:117-32.  Back to cited text no. 6
    
7.Dufès C, Uchegbu IF, Schätzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005;57:2177-202.  Back to cited text no. 7
    
8.Tolia GT, Choi HH. The role of dendrimers in topical drug delivery. Pharm Technol 2008;32:88-98.  Back to cited text no. 8
    
9.Swanson DR, Huang B, Abdelhady HG, Tomalia DA. Unique steric and geometry induced stoichiometries observed in the divergent synthesis of poly (ester-acrylate/amine) (PEA) dendrimers. New J Chem 2007;31:1368-78.  Back to cited text no. 9
    
10.Tomalia DA, Fréchet JM. Discovery of dendrimers and dendritic polymers: A brief historical perspective*. J Polym Sci A Polym Chem 2002;40:2719-28.  Back to cited text no. 10
    
11.Tomalia DA, Rookmaker M. Poly (propylene imine) dendrimers. Polymer Data Handbook. NewYork: Oxford University Press; 2009.  Back to cited text no. 11
    
12.Patton DL, Cosgrove Sweeney YT, McCarthy TD, Hillier SL. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob Agents Chemother 2006;50:1696-700.  Back to cited text no. 12
    
13.Singh P. Dendrimers and their applications in immunoassays and clinical diagnostics. Biotechnol Appl Biochem 2007;48:1-9.  Back to cited text no. 13
    
14.Hill SW, Heidecker G. Transfection of hematopoetic cells in suspension using an activated-dendrimer reagent. In Qiagen News. Sect. 8-10. 1998.  Back to cited text no. 14
    
15.Liu H, Wang H, Yang W, Cheng Y. Disulfide cross-linked low generation dendrimers with high gene transfection efficacy, low cytotoxicity, and low cost. J Am Chem Soc 2012;134:17680-7.  Back to cited text no. 15
    
16.Spangler BD. Inventor biosensors utilizing dendrimer-immobilized ligands and there use thereof patent. United States Patent 7138121. 2006.  Back to cited text no. 16
    
17.Available from: http://www.starpharma.com/news/132.  Back to cited text no. 17
    
18.Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev 2008;60:1037-55.  Back to cited text no. 18
    
19.Mintzer MA, Grinstaff MW. Biomedical applications of dendrimers: A tutorial. Chem Soc Rev 2011;40:173-90.  Back to cited text no. 19
    
20.Hawker CJ, Frechet JM. Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J Am Chem Soc 1990;112:7638-47.  Back to cited text no. 20
    
21.Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK. Dendrimers: Emerging polymers for drug-delivery systems. Eur J Pharm Sci 2009;38:185-96.  Back to cited text no. 21
    
22.Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev 2012;64 Suppl:102-15.  Back to cited text no. 22
    
23.Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science 2004;303:1818-22.  Back to cited text no. 23
    
24.Soto-Castro D, Cruz-Morales JA, Ramírez Apan MT, Guadarrama P. Solubilization and anticancer-activity enhancement of Methotrexate by novel dendrimeric nanodevices synthesized in one-step reaction. Bioorg Chem 2012;41-2:13-21.  Back to cited text no. 24
    
25.Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 2005;57:2215-37.  Back to cited text no. 25
    
26.Tomalia DA. Birth of a new macromolecular architecture: Dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog Polym Sci 2005;30:294-324.  Back to cited text no. 26
    
27.Kitchens KM, El-Sayed ME, Ghandehari H. Transepithelial and endothelial transport of poly (amidoamine) dendrimers. Adv Drug Deliv Rev 2005;57:2163-76.  Back to cited text no. 27
    
28.Morgan MT, Carnahan MA, Immoos CE, Ribeiro AA, Finkelstein S, Lee SJ, et al. Dendritic molecular capsules for hydrophobic compounds. J Am Chem Soc 2003;125:15485-9.  Back to cited text no. 28
    
29.Morgan MT, Nakanishi Y, Kroll DJ, Griset AP, Carnahan MA, Wathier M, et al. Dendrimer-encapsulated camptothecins: Increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res 2006;66:11913-21.  Back to cited text no. 29
    
30.Ooya T, Lee J, Park K. Hydrotropic dendrimers of generations 4 and 5: Synthesis, characterization, and hydrotropic solubilization of paclitaxel. Bioconjug Chem 2004;15:1221-9.  Back to cited text no. 30
    
31.Khandare JJ, Jayant S, Singh A, Chandna P, Wang Y, Vorsa N, et al. Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjug Chem 2006;17:1464-72.  Back to cited text no. 31
    
32.Teow HM, Zhou Z, Najlah M, Yusof SR, Abbott NJ, D'Emanuele A. Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int J Pharm 2013;441:701-11.  Back to cited text no. 32
    
33.Zhou Z, D'Emanuele A, Attwood D. Solubility enhancement of paclitaxel using a linear-dendritic block copolymer. Int J Pharm 2013;452:173-9.  Back to cited text no. 33
    
34.Gurdag S, Khandare J, Stapels S, Matherly LH, Kannan RM. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and-resistant cell lines. Bioconjug Chem 2006;17:275-83.  Back to cited text no. 34
    
35.Patri AK, Kukowska-Latallo JF, Baker JR Jr. Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 2005;57:2203-14.  Back to cited text no. 35
    
36.Papagiannaros A, Dimas K, Papaioannou GT, Demetzos C. Doxorubicin-PAMAM dendrimer complex attached to liposomes: Cytotoxic studies against human cancer cell lines. Int J Pharm 2005;302:29-38.  Back to cited text no. 36
    
37.Kaminskas LM, McLeod VM, Kelly BD, Sberna G, Boyd BJ, Williamson M, et al. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine 2012;8:103-11.  Back to cited text no. 37
    
38.Lee CC, Gillies ER, Fox ME, Guillaudeu SJ, Fréchet JM, Dy EE, et al. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci U S A 2006;103:16649-54.  Back to cited text no. 38
    
39.Gupta U, Agashe HB, Jain NK. Polypropylene imine dendrimer mediated solubility enhancement: Effect of pH and functional groups of hydrophobes. J Pharm Pharm Sci 2007;10:358-67.  Back to cited text no. 39
    
40.Kumar PV, Asthana A, Dutta T, Jain NK. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target 2006;14:546-56.  Back to cited text no. 40
    
41.Dutta T, Jain NK. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim Biophys Acta 2007;1770:681-6.  Back to cited text no. 41
    
42.Dutta T, Garg M, Jain NK. Targeting of efavirenz loaded tuftsin conjugated poly (propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur J Pharm Sci 2008;34:181-9.  Back to cited text no. 42
    
43.Devarakonda B, Otto DP, Judefeind A, Hill RA, de Villiers MM. Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. Int J Pharm 2007;345:142-53.  Back to cited text no. 43
    
44.Wang F, Bronich TK, Kabanov AV, Rauh RD, Roovers J. Synthesis and evaluation of a star amphiphilic block copolymer from poly (epsilon-caprolactone) and poly (ethylene glycol) as a potential drug delivery carrier. Bioconjug Chem 2005;16:397-405.  Back to cited text no. 44
    
45.Bosnjakovic A, Mishra MK, Ren W, Kurtoglu YE, Shi T, Fan D, et al. Poly (amidoamine) dendrimer-erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation. Nanomedicine 2011;7:284-94.  Back to cited text no. 45
    
46.Gajbhiye V, Ganesh N, Barve J, Jain NK. Synthesis, characterization and targeting potential of zidovudine loaded sialic acid conjugated-mannosylated poly (propyleneimine) dendrimers. Eur J Pharm Sci 2013;48:668-79.  Back to cited text no. 46
    
47.Cheng Y, Man N, Xu T, Fu R, Wang X, Wang X, et al. Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. J Pharm Sci 2007;96:595-602.  Back to cited text no. 47
    
48.Jin Y, Ren X, Wang W, Ke L, Ning E, Du L, et al. A 5-fluorouracil-loaded pH-responsive dendrimer nanocarrier for tumor targeting. Int J Pharm 2011;420:378-84.  Back to cited text no. 48
    
49.D'Emanuele A, Jevprasesphant R, Penny J, Attwood D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release 2004;95:447-53.  Back to cited text no. 49
    
50.Najlah M, Freeman S, Attwood D, D'Emanuele A. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Int J Pharm 2007;336:183-90.  Back to cited text no. 50
    
51.Vandamme TF, Brobeck L. Poly (amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 2005;102:23-38.  Back to cited text no. 51
    
52.Devarakonda B, Hill RA, Liebenberg W, Brits M, de Villiers MM. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int J Pharm 2005;304:193-209.  Back to cited text no. 52
    
53.Ma M, Cheng Y, Xu Z, Xu P, Qu H, Fang Y, et al. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug. Eur J Med Chem 2007;42:93-8.  Back to cited text no. 53
    
54.Devarakonda B, Li N, de Villiers MM. Effect of polyamidoamine (PAMAM) dendrimers on the in vitro release of water-insoluble nifedipine from aqueous gels. AAPS PharmSciTech 2005;6:E504-12.  Back to cited text no. 54
    
55.Holden CA, Tyagi P, Thakur A, Kadam R, Jadhav G, Kompella UB, et al. Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine 2012;8:776-83.  Back to cited text no. 55
    
56.Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci 2013; [In press].  Back to cited text no. 56
    
57.Myc A, Majoros IJ, Thomas TP, Baker JR Jr. Dendrimer-based targeted delivery of an apoptotic sensor in cancer cells. Biomacromolecules 2007;8:13-8.  Back to cited text no. 57
    
58.Wang Y, Guo R, Cao X, Shen M, Shi X. Encapsulation of 2-methoxyestradiol within multifunctional poly (amidoamine) dendrimers for targeted cancer therapy. Biomaterials 2011;32:3322-9.  Back to cited text no. 58
    
59.Sideratou Z, Kontoyianni C, Drossopoulou GI, Paleos CM. Synthesis of a folate functionalized PEGylated poly (propylene imine) dendrimer as prospective targeted drug delivery system. Bioorg Med Chem Lett 2010;20:6513-7.  Back to cited text no. 59
    
60.Gupta U, Dwivedi SK, Bid HK, Konwar R, Jain NK. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. Int J Pharm 2010;393:185-96.  Back to cited text no. 60
    
61.Patri AK, Myc A, Beals J, Thomas TP, Bander NH, Baker JR Jr. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004;15:1174-81.  Back to cited text no. 61
    
62.Wu G, Barth RF, Yang W, Kawabata S, Zhang L, Green-Church K. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther 2006;5:52-9.  Back to cited text no. 62
    
63.Shukla R, Thomas TP, Desai AM, Kotlyar A, Park SJ, Baker JR. HER2 specific delivery of methotrexate by dendrimer conjugated anti-HER2 mAb. Nanotechnology 2008;19:295102.  Back to cited text no. 63
    
64.Lagnoux D, Darbre T, Schmitz ML, Reymond JL. Inhibition of mitosis by glycopeptide dendrimer conjugates of colchicine. Chemistry 2005;11:3941-50.  Back to cited text no. 64
    
65.Ciolkowski M, Pa³ecz B, Appelhans D, Voit B, Klajnert B, Bryszewska M. The influence of maltose modified poly (propylene imine) dendrimers on hen egg white lysozyme structure and thermal stability. Colloids Surf B Biointerfaces 2012;95:103-8.  Back to cited text no. 65
    
66.Santos JL, Pandita D, Rodrigues J, Pêgo AP, Granja PL, Tomás H. Non-viral gene delivery to mesenchymal stem cells: Methods, strategies and application in bone tissue engineering and regeneration. Curr Gene Ther 2011;11:46-57.  Back to cited text no. 66
    
67.Tack F, Bakker A, Maes S, Dekeyser N, Bruining M, Elissen-Roman C, et al. Modified poly (propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes). J Drug Target 2006;14:69-86.  Back to cited text no. 67
    
68.Pandita D, Santos JL, Rodrigues J, Pêgo AP, Granja PL, Tomás H. Gene delivery into mesenchymal stem cells: A biomimetic approach using RGD nanoclusters based on poly (amidoamine) dendrimers. Biomacromolecules 2011;12:472-81.  Back to cited text no. 68
    
69.Santos JL, Oliveira H, Pandita D, Rodrigues J, Pêgo AP, Granja PL, et al. Functionalization of poly (amidoamine) dendrimers with hydrophobic chains for improved gene delivery in mesenchymal stem cells. J Control Release 2010;144:55-64.  Back to cited text no. 69
    
70.Santos JL, Pandita D, Rodrigues J, Pêgo AP, Granja PL, Balian G, et al. Receptor-mediated gene delivery using PAMAM dendrimers conjugated with peptides recognized by mesenchymal stem cells. Mol Pharm 2010;7:763-74.  Back to cited text no. 70
    
71.Daftarian P, Kaifer AE, Li W, Blomberg BB, Frasca D, Roth F, et al. Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells. Cancer Res 2011;71:7452-62.  Back to cited text no. 71
    
72.Bai CZ, Choi S, Nam K, An S, Park JS. Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant glioma. Int J Pharm 2013;445:79-87.  Back to cited text no. 72
    
73.Shan Y, Luo T, Peng C, Sheng R, Cao A, Cao X, et al. Gene delivery using dendrimer-entrapped gold nanoparticles as nonviral vectors. Biomaterials 2012;33:3025-35.  Back to cited text no. 73
    
74.Ferenc M, Pedziwiatr-Werbicka E, Nowak KE, Klajnert B, Majoral JP, Bryszewska M. Phosphorus dendrimers as carriers of siRNA - Characterisation of dendriplexes. Molecules 2013;18:4451-66.  Back to cited text no. 74
    
75.Drzewin´ska J, Appelhans D, Voit B, Bryszewska M, Klajnert B. Poly (propylene imine) dendrimers modified with maltose or maltotriose protect phosphorothioate oligodeoxynucleotides against nuclease activity. Biochem Biophys Res Commun 2012;427:197-201.  Back to cited text no. 75
    
76.Nam HY, Nam K, Lee M, Kim SW, Bull DA. Dendrimer type bio-reducible polymer for efficient gene delivery. J Control Release 2012;160:592-600.  Back to cited text no. 76
    
77.Cloninger MJ . Biological applications of dendrimers. Curr Opin Chem Biol 2002;6:742-8.  Back to cited text no. 77
    
78.Jang WD, Kamruzzaman Selim KM, Lee CH, Kang IK. Bioinspired application of dendrimers: From bio-mimicry to biomedical applications. Prog Polym Sci 2009;34:1-23.  Back to cited text no. 78
    
79.Cheng Y, Wu Q, Li Y, Hu J, Xu T. New insights into the interactions between dendrimers and surfactants: 2. Design of new drug formulations based on dendrimer-surfactant aggregates. J Phys Chem B 2009;113:8339-46.  Back to cited text no. 79
    
80.Jansen JF, de Brabander-van den Berg EM, Meijer EW. Encapsulation of guest molecules into a dendritic box. Science 1994;266:1226-9.  Back to cited text no. 80
    
81.D'Emanuele A, Attwood D. Dendrimer-drug interactions. Adv Drug Deliv Rev 2005;57:2147-62.  Back to cited text no. 81
    
82.Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 2003;259:143-60.  Back to cited text no. 82
    
83.Prajapati RN, Tekade RK, Gupta U, Gajbhiye V, Jain NK. Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. Mol Pharm 2009;6:940-50.  Back to cited text no. 83
    
84.Chauhan AS, Sridevi S, Chalasani KB, Jain AK, Jain SK, Jain NK, et al. Dendrimer-mediated transdermal delivery: Enhanced bioavailability of indomethacin. J Control Release 2003;90:335-43.  Back to cited text no. 84
    
85.Beezer AE, King AS, Martin IK, Mitchel JC, Twyman LJ, Wain CF. Dendrimers as potential drug carriers; encapsulation of acidic hydrophobes within water soluble PAMAM derivatives. Tetrahedron 2003;59:3873-80.  Back to cited text no. 85
    
86.Yang H, Lopina ST. Penicillin V-conjugated PEG-PAMAM star polymers. J Biomater Sci Polym Ed 2003;14:1043-56.  Back to cited text no. 86
    
87.Yang H, Lopina ST. Extended release of a novel antidepressant, venlafaxine, based on anionic polyamidoamine dendrimers and poly (ethylene glycol)-containing semi-interpenetrating networks. J Biomed Mater Res A 2005;72:107-14.  Back to cited text no. 87
    
88.Wiwattanapatapee R, Lomlim L, Saramunee K. Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. J Control Release 2003;88:1-9.  Back to cited text no. 88
    
89.Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: A novel approach to cancer chemotherapy. Anticancer Drugs 1999;10:767-76.  Back to cited text no. 89
    
90.Pasut G, Scaramuzza S, Schiavon O, Mendichi R, Veronese FM. PEG-epirubicin conjugates with high drug loading. J Bioact Compat Polym 2005;20:213-30.  Back to cited text no. 90
    
91.Caminade AM, Laurent R, Majoral JP. Characterization of dendrimers. Adv Drug Deliv Rev 2005;57:2130-46.  Back to cited text no. 91
    
92.Biricova V, Laznickova A. Dendrimers: Analytical characterization and applications. Bioorg Chem 2009;37:185-92.  Back to cited text no. 92
    
93.Huang X, Wu Z, Gao W, Chen Q, Yu B. Polyamidoamine dendrimers as potential drug carriers for enhanced aqueous solubility and oral bioavailability of silybin. Drug Dev Ind Pharm 2011;37:419-27.  Back to cited text no. 93
    
94.Perez AP, Romero EL, Morilla MJ. Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. Int J Pharm 2009;380:189-200.  Back to cited text no. 94
    
95.Hu J, Su Y, Zhang H, Xu T, Cheng Y. Design of interior-functionalized fully acetylated dendrimers for anticancer drug delivery. Biomaterials 2011;32:9950-9.  Back to cited text no. 95
    
96.Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis. Biomaterials 2003;24:1121-31.  Back to cited text no. 96
    
97.Rittner K, Benavente A, Bompard-Sorlet A, Heitz F, Divita G, Brasseur R, et al. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol Ther 2002;5:104-14.  Back to cited text no. 97
    
98.Mecke A, Majoros IJ, Patri AK, Baker JR Jr, Holl MM, Orr BG. Lipid bilayer disruption by polycationic polymers: The roles of size and chemical functional group. Langmuir 2005;21:10348-54.  Back to cited text no. 98
    
99.Chen HT, Neerman MF, Parrish AR, Simanek EE. Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J Am Chem Soc 2004;126:10044-8.  Back to cited text no. 99
    
100.Mecke A, Lee DK, Ramamoorthy A, Orr BG, Holl MM. Synthetic and natural polycationic polymer nanoparticles interact selectively with fluid-phase domains of DMPC lipid bilayers. Langmuir 2005;21:8588-90.  Back to cited text no. 100
    
101.Doman´ski DM, Klajnert B, Bryszewska M. Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry 2004;63:189-91.  Back to cited text no. 101
    
102.Jevprasesphant R, Penny J, Jalal R, Attwood D, McKeown NB, D'Emanuele A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 2003;252:263-6.  Back to cited text no. 102
    
103.Kitchens KM, Foraker AB, Kolhatkar RB, Swaan PW, Ghandehari H. Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells. Pharm Res 2007;24:2138-45.  Back to cited text no. 103
    
104.Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res 1996;30:53-65.  Back to cited text no. 104
    
105.Bourne N, Stanberry LR, Kern ER, Holan G, Matthews B, Bernstein DI. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother 2000;44:2471-4.  Back to cited text no. 105
    
106.Jones CF, Campbell RA, Franks Z, Gibson CC, Thiagarajan G, Vieira-de-Abreu A, et al. Cationic PAMAM dendrimers disrupt key platelet functions. Mol Pharm 2012;9:1599-611.  Back to cited text no. 106
    
107.Dutta T, Garg M, Dubey V, Mishra D, Singh K, Pandita D, et al. Toxicological investigation of surface engineered fifth generation poly (propyleneimine) dendrimers in vivo. Nanotoxicology 2008;2:62-70.  Back to cited text no. 107
    
108.Thiagarajan G, Greish K, Ghandehari H. Charge affects the oral toxicity of poly (amidoamine) dendrimers. Eur J Pharm Biopharm 2013;84:330-4.  Back to cited text no. 108
    
109.Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: Let's meet the challenge. Int J Pharm 2010;394:122-42.  Back to cited text no. 109
    
110.Battah S, O'Neill S, Edwards C, Balaratnam S, Dobbin P, MacRobert AJ. Enhanced porphyrin accumulation using dendritic derivatives of 5-aminolaevulinic acid for photodynamic therapy: An in vitro study. Int J Biochem Cell Biol 2006;38:1382-92.  Back to cited text no. 110
    
111.Battah S, Balaratnam S, Casas A, O'Neill S, Edwards C, Batlle A, et al. Macromolecular delivery of 5-aminolaevulinic acid for photodynamic therapy using dendrimer conjugates. Mol Cancer Ther 2007;6:876-85.  Back to cited text no. 111
    
112.Di Venosa GM, Casas AG, Battah S, Dobbin P, Fukuda H, Macrobert AJ, et al. Investigation of a novel dendritic derivative of 5-aminolaevulinic acid for photodynamic therapy. Int J Biochem Cell Biol 2006;38:82-91.  Back to cited text no. 112
    
113.Herlambang S, Kumagai M, Nomoto T, Horie S, Fukushima S, Oba M, et al. Disulfide crosslinked polyion complex micelles encapsulating dendrimer phthalocyanine directed to improved efficiency of photodynamic therapy. J Control Release 2011;155:449-57.  Back to cited text no. 113
    
114.Tao X, Yang YJ, Liu S, Zheng YZ, Fu J, Chen JF. Poly (amidoamine) dendrimer-grafted porous hollow silica nanoparticles for enhanced intracellular photodynamic therapy. Acta Biomater 2013;9:6431-8.  Back to cited text no. 114
    
115.Barth RF, Soloway AH, Fairchild RG, Brugger RM. Boron neutron capture therapy for cancer. Realities and prospects. Cancer 1992;70:2995-3007.  Back to cited text no. 115
    
116.Barth RF, Wu G, Yang W, Binns PJ, Riley KJ, Patel H, et al. Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent. Appl Radiat Isot 2004;61:899-903.  Back to cited text no. 116
    
117.Yang W, Barth RF, Wu G, Tjarks W, Binns P, Riley K. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Appl Radiat Isot 2009;67:S328-31.  Back to cited text no. 117
    
118.Kobayashi H, Reijnders K, English S, Yordanov AT, Milenic DE, Sowers AL, et al. Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin Cancer Res 2004;10:7712-20.  Back to cited text no. 118
    
119.Wiener EC, Brechbiel MW, Brothers H, Magin RL, Gansow OA, Tomalia DA, et al. Dendrimer-based metal chelates: A new class of magnetic resonance imaging contrast agents. Magn Reson Med 1994;31:1-8.  Back to cited text no. 119
    
120.Ye M, Qian Y, Tang J, Hu H, Sui M, Shen Y. Targeted biodegradable dendritic MRI contrast agent for enhanced tumor imaging. J Control Release 2013;169:239-45.  Back to cited text no. 120
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]
 
 
    Tables

  [Table 1], [Table 2]


This article has been cited by
1 Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV -1 vaginal microbicides
Ignacio Rodríguez-Izquierdo, Daniel Sepúlveda-Crespo, Jose María Lasso, Salvador Resino, Ma Ángeles Muñoz-Fernández
WIREs Nanomedicine and Nanobiotechnology. 2022;
[Pubmed] | [DOI]
2 Targeting neuroinflammation by intranasal delivery of nanoparticles in neurological diseases: a comprehensive review
Fatemeh Moradi, Nasrin Dashti
Naunyn-Schmiedeberg's Archives of Pharmacology. 2022;
[Pubmed] | [DOI]
3 Future of Alzheimer’s Disease: Nanotechnology-Based Diagnostics and Therapeutic Approach
Gopikrishna Agraharam, Nishakavya Saravanan, Agnishwar Girigoswami, Koyeli Girigoswami
BioNanoScience. 2022;
[Pubmed] | [DOI]
4 Nano to rescue: repository of nanocarriers for targeted drug delivery to curb breast cancer
Poonam Banthia, Lokesh Gambhir, Asha Sharma, Dhiraj Daga, Neha Kapoor, Rishabh Chaudhary, Gaurav Sharma
3 Biotech. 2022; 12(3)
[Pubmed] | [DOI]
5 Delivery Strategies for CRISPR/Cas Genome editing tool for Retinal Dystrophies: challenges and opportunities
Aayushi Lohia, Deepak Kumar Sahel, Mohammad Salman, Vivek Singh, Indumathi Mariappan, Anupama Mittal, Deepak Chitkara
Asian Journal of Pharmaceutical Sciences. 2022;
[Pubmed] | [DOI]
6 Drug-dendrimer complexes and conjugates: Detailed furtherance through theory and experiments
Rohit Y. Sathe, Prasad V. Bharatam
Advances in Colloid and Interface Science. 2022; : 102639
[Pubmed] | [DOI]
7 Combination of ovalbumin-coated iron oxide nanoparticles and poly(amidoamine) dendrimer-cisplatin nanocomplex for enhanced anticancer efficacy
Tefera Worku Mekonnen, Haile Fentahun Darge, Yihenew Simegniew Birhan, Endiries Yibru Hanurry, Hailemichael Tegenu Gebrie, Hsiao-Ying Chou, Juin-Yih Lai, Shinn-Zong Lin, Horng-Jyh Harn, Yu-Shuan Chen, Hsieh-Chih Tsai
Colloids and Surfaces B: Biointerfaces. 2022; : 112391
[Pubmed] | [DOI]
8 Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy
Shreyas Mukherjee, Samrat Mukherjee, Mohammed A.S. Abourehab, Amirhossein Sahebkar, Prashant Kesharwani
European Polymer Journal. 2022; : 111471
[Pubmed] | [DOI]
9 Dendrimers as prospective nanocarrier for targeted delivery against lung cancer
Virali Arora, Mohammed A. S. Abourehab, Gyan Modi, Prashant Kesharwani
European Polymer Journal. 2022; : 111635
[Pubmed] | [DOI]
10 Polymer-drug conjugates: Design principles, emerging synthetic strategies and clinical overview
Ankit Javia, Jigar Vanza, Denish Bardoliwala, Saikat Ghosh, Ambikanandan Misra, Mrunali Patel, Hetal Thakkar
International Journal of Pharmaceutics. 2022; : 121863
[Pubmed] | [DOI]
11 Dendritic peptide-conjugated polymeric nanovectors for non-toxic delivery of plasmid DNA and enhanced non-viral transfection of immune cells
Sijia Yi, Sun-Young Kim, Michael P. Vincent, Simseok A. Yuk, Sharan Bobbala, Fanfan Du, Evan Alexander Scott
iScience. 2022; 25(7): 104555
[Pubmed] | [DOI]
12 Overcoming skin barriers through advanced transdermal drug delivery approaches
Vivek Phatale, Klaudi K. Vaiphei, Shikha Jha, Dnyaneshwar Patil, Mukta Agrawal, Amit Alexander
Journal of Controlled Release. 2022; 351: 361
[Pubmed] | [DOI]
13 Engineering hybrid nanosystems for efficient and targeted delivery against bacterial infections
Eman Elhassan, Nikita Devnarain, Mahir Mohammed, Thirumala Govender, Calvin A. Omolo
Journal of Controlled Release. 2022; 351: 598
[Pubmed] | [DOI]
14 Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis
Luis Ángel Ibarra-Sánchez, Ana Gámez-Méndez, Manuel Martínez-Ruiz, Erik Francisco Nájera-Martínez, Brando Alan Morales-Flores, Elda M. Melchor-Martínez, Juan Eduardo Sosa-Hernández, Roberto Parra-Saldívar, Hafiz M.N. Iqbal
Journal of Drug Delivery Science and Technology. 2022; : 103219
[Pubmed] | [DOI]
15 Recent advances in drug delivery nanocarriers incorporated in temperature-sensitive Pluronic F-127–A critical review
Rose Jaquilin P J, Oluwatobi S. Oluwafemi, Sabu Thomas, Adebola Oyedeji
Journal of Drug Delivery Science and Technology. 2022; : 103390
[Pubmed] | [DOI]
16 Dendrimers in the context of targeting central nervous system disorders
Forum Palan, Bappaditya Chatterjee
Journal of Drug Delivery Science and Technology. 2022; : 103474
[Pubmed] | [DOI]
17 Doxorubicin and Imatinib co-drug delivery using non-covalently functionalized carbon nanotube: Molecular dynamics study
Abdolhalim Torrik, Shamim Zaerin, Mahdi Zarif
Journal of Molecular Liquids. 2022; : 119789
[Pubmed] | [DOI]
18 Paclitaxel-conjugated phenylboronic acid-enriched catalytic robots as smart drug delivery systems
Sezin Eren Demirbuken, Gozde Yurdabak Karaca, Hilmi Kaan Kaya, Lutfi Oksuz, Bora Garipcan, Aysegul Uygun Oksuz, Filiz Kuralay
Materials Today Chemistry. 2022; 26: 101172
[Pubmed] | [DOI]
19 Stimuli responsive nano-composite co-delivery of Doxorubicin and ciprofloxacin using HPLC-UV combined spectroscopy methods
Mahta Badinezhad, Majid Soleimani, Samira Jafari
Materials Today Communications. 2022; 30: 103128
[Pubmed] | [DOI]
20 Reactive oxygen nano-generators for cancer therapy
Dnyaneshwar Kalyane, Devendra Choudhary, Suryanarayana Polaka, Hanmant Goykar, Tukaram Karanwad, Kuldeep Rajpoot, Rakesh Kumar Tekade
Progress in Materials Science. 2022; : 100974
[Pubmed] | [DOI]
21 Biopolymers based Aerogels: A Review on Revolutionary Solutions for Smart Therapeutics Delivery
H.P.S. Abdul Khalil, Esam Bashir Yahya, Fauziah Jummaat, A.S. Adnan, N.G. Olaiya, Samsul Rizal, C.K. Abdullah, Daniel Pasquini, Sabu Thomas
Progress in Materials Science. 2022; : 101014
[Pubmed] | [DOI]
22 Simultaneous removal of pollutants from sub-nanometric to nanometric scales by hierarchical dendrimers modified aerogels
Zhichao He, Fan Wu, Li Liu, Xin Song, Shengjie Guan, Zhonghua Li, Jun Li, Yudong Huang
Separation and Purification Technology. 2022; 286: 120440
[Pubmed] | [DOI]
23 Dendrimers as nanoscale vectors: Unlocking the bars of cancer therapy
Asmita Deka Dey, Ashkan Bigham, Yasaman Esmaeili, Milad Ashrafizadeh, Farnaz Dabbagh Moghaddam, Shing Cheng Tan, Satar Yousefiasl, Saurav Sharma, Aziz Maleki, Navid Rabiee, Alan Prem Kumar, Vijay Kumar Thakur, Gorka Orive, Esmaeel Sharifi, Arun Kumar, Pooyan Makvandi
Seminars in Cancer Biology. 2022;
[Pubmed] | [DOI]
24 Dendrimer-based drug delivery systems: history, challenges, and latest developments
Juan Wang, Boxuan Li, Li Qiu, Xin Qiao, Hu Yang
Journal of Biological Engineering. 2022; 16(1)
[Pubmed] | [DOI]
25 Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity
Gandarvakottai Senthilkumar Arumugam, Kannan Damodharan, Mukesh Doble, Sathiah Thennarasu
Molecular Biomedicine. 2022; 3(1)
[Pubmed] | [DOI]
26 Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Adil A. Sayyed, Piyush Gondaliya, Palak Bhat, Mukund Mali, Neha Arya, Amit Khairnar, Kiran Kalia
Current Pharmaceutical Design. 2022; 28(6): 471
[Pubmed] | [DOI]
27 Virus as a Nanocarrier for Drug Delivery Redefining Medical Therapeutics - A Status Report
Sanjay Kumar Ojha, Ritesh Pattnaik, Puneet Kumar Singh, Shubha Dixit, Snehasish Mishra, Sreyasi Pal, Subrat Kumar
Combinatorial Chemistry & High Throughput Screening. 2022; 25(10): 1619
[Pubmed] | [DOI]
28 Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple- Negative Breast Cancer (TNBC)
Abhishek Kanugo, Rupesh K. Gautam, Mohammad Amjad Kamal
Current Pharmaceutical Biotechnology. 2022; 23(13): 1581
[Pubmed] | [DOI]
29 Recent Developments in Biopolymeric Nanoparticles for Drug Delivery Systems: An Overview
Soumya R. Barik, Ranjan K. Mohapatra, Pranab K. Mohapatra, Ahmed Mahal, Marei M. El-Ajaily
Micro and Nanosystems. 2022; 14(2): 92
[Pubmed] | [DOI]
30 Considerations for Polymers Used in Ocular Drug Delivery
Megan M. Allyn, Richard H. Luo, Elle B. Hellwarth, Katelyn E. Swindle-Reilly
Frontiers in Medicine. 2022; 8
[Pubmed] | [DOI]
31 A spotlight on alkaloid nanoformulations for the treatment of lung cancer
Sindhoor S. M., N. Raghavendra Naveen, GSN Koteswara Rao, Gopika Gopan, Hitesh Chopra, Moon Nyeo Park, Mohammed Merae Alshahrani, Jobin Jose, Talha Bin Emran, Bonglee Kim
Frontiers in Oncology. 2022; 12
[Pubmed] | [DOI]
32 Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery System
Farahidah Mohamed, May K. Oo, Bappaditya Chatterjee, Batoul Alallam
Frontiers in Pharmacology. 2022; 13
[Pubmed] | [DOI]
33 Sustained Drug Release from Smart Nanoparticles in Cancer Therapy: A Comprehensive Review
Xue Bai, Zara Smith, Yuheng Wang, Sam Butterworth, Annalisa Tirella
Micromachines. 2022; 13(10): 1623
[Pubmed] | [DOI]
34 An Overview of Nanotechnologies for Drug Delivery to the Brain
Ahsan Ayub, Shawn Wettig
Pharmaceutics. 2022; 14(2): 224
[Pubmed] | [DOI]
35 Functionalization of Nanoparticulate Drug Delivery Systems and Its Influence in Cancer Therapy
Theodora Amanda Seidu, Perpetua Takunda Kutoka, Dorothy Owusu Asante, Muhammad Asim Farooq, Raphael N. Alolga, Wang Bo
Pharmaceutics. 2022; 14(5): 1113
[Pubmed] | [DOI]
36 Safety Challenges and Application Strategies for the Use of Dendrimers in Medicine
Xiang Li, Abid Naeem, Shanghua Xiao, Lei Hu, Jing Zhang, Qin Zheng
Pharmaceutics. 2022; 14(6): 1292
[Pubmed] | [DOI]
37 Chlorotoxin and Lung Cancer: A Targeting Perspective for Drug Delivery
Archana Shrestha, Behnaz Lahooti, Constantinos M. Mikelis, George Mattheolabakis
Pharmaceutics. 2022; 14(12): 2613
[Pubmed] | [DOI]
38 A Review on Poly(amidoamine) Dendrimers: Properties, Synthesis, and Characterization Prospects
Piyushkumar Sadhu, Mamta Kumari, Falguni Rathod, Niyati Shah, Shivkant Patel
Archives of Pharmacy Practice. 2022; 13(4): 1
[Pubmed] | [DOI]
39 Stimuli-Responsive Polymeric Nanoplatforms for Cancer Therapy
Di Chang, Yuanyuan Ma, Xiaoxuan Xu, Jinbing Xie, Shenghong Ju
Frontiers in Bioengineering and Biotechnology. 2021; 9
[Pubmed] | [DOI]
40 Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities
Abhiram Natu, Anjali Singh, Sanjay Gupta
World Journal of Hepatology. 2021; 13(11): 1568
[Pubmed] | [DOI]
41 Chiral Recognition of Homochiral Poly (amidoamine) Dendrimers Substituted with R- and S-Glycidol by Keratinocyte (HaCaT) and Squamous Carcinoma (SCC-15) Cells In Vitro
Malgorzata Malinga-Drozd, Lukasz Uram, Konrad Wróbel, Stanislaw Wolowiec
Polymers. 2021; 13(7): 1049
[Pubmed] | [DOI]
42 Nano Drug Delivery Platforms for Dental Application: Infection Control and TMJ Management—A Review
Abhishek Lal, Mohammad Khursheed Alam, Naseer Ahmed, Afsheen Maqsood, Ruba K. Al-Qaisi, Deepti Shrivastava, Zainab Ali Alkhalaf, Amal Mohamed Alanazi, Hasna Rasheed Alshubrmi, Mohammed G. Sghaireen, Kumar Chandan Srivastava
Polymers. 2021; 13(23): 4175
[Pubmed] | [DOI]
43 Analysis of Fractal Structures in Dehydrated Films of Protein Solutions
Maksim Baranov, Elena Velichko, Konstantin Greshnevikov
Symmetry. 2021; 13(1): 123
[Pubmed] | [DOI]
44 Molecular Modelling Guided Modulation of Molecular Shape and Charge for Design of Smart Self-Assembled Polymeric Drug Transporters
Sousa Javan Nikkhah, Damien Thompson
Pharmaceutics. 2021; 13(2): 141
[Pubmed] | [DOI]
45 Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes
Kenneth Omabe, Clément Paris, François Lannes, David Taïeb, Palma Rocchi
Pharmaceutics. 2021; 13(5): 591
[Pubmed] | [DOI]
46 Photochemical Internalization of Etoposide Using Dendrimer Nanospheres Loaded with Etoposide and Protoporphyrin IX on a Glioblastoma Cell Line
Martin Hsiu-Chu Lin, Li-Ching Chang, Chiu-Yen Chung, Wei-Chao Huang, Ming-Hsueh Lee, Kuo-Tai Chen, Ping-Shan Lai, Jen-Tsung Yang
Pharmaceutics. 2021; 13(11): 1877
[Pubmed] | [DOI]
47 Biocompatible Nanocarriers for Enhanced Cancer Photodynamic Therapy Applications
Sathish Sundar Dhilip Kumar, Heidi Abrahamse
Pharmaceutics. 2021; 13(11): 1933
[Pubmed] | [DOI]
48 Peptide-Functionalized Dendrimer Nanocarriers for Targeted Microdystrophin Gene Delivery
Jessica Hersh, José Manuel Condor Capcha, Camila Iansen Irion, Guerline Lambert, Mauricio Noguera, Mohit Singh, Avinash Kaur, Emre Dikici, Joaquín J. Jiménez, Lina A. Shehadeh, Sylvia Daunert, Sapna K. Deo
Pharmaceutics. 2021; 13(12): 2159
[Pubmed] | [DOI]
49 Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases
Giulia Paolini Sguazzi, Valentina Muto, Marco Tartaglia, Enrico Bertini, Claudia Compagnucci
International Journal of Molecular Sciences. 2021; 22(24): 13674
[Pubmed] | [DOI]
50 The Nanosystems Involved in Treating Lung Cancer
Andreea Crintea, Alina Gabriela Dutu, Gabriel Samasca, Ioan Alexandru Florian, Iulia Lupan, Alexandra Marioara Craciun
Life. 2021; 11(7): 682
[Pubmed] | [DOI]
51 Peptide Multimerization as Leads for Therapeutic Development
Dean E. Sheard, Wenyi Li, Neil M. O’Brien-Simpson, Frances Separovic, John D. Wade
Biologics. 2021; 2(1): 15
[Pubmed] | [DOI]
52 Blood Compatibility of Amphiphilic Phosphorous Dendrons—Prospective Drug Nanocarriers
Simon Suty, Veronika Oravczova, Zuzana Garaiova, Veronika Subjakova, Maksim Ionov, Dzmitry Shcharbin, Zuzana Simonikova, Peter Bartek, Milan Zvarik, Xiangyang Shi, Serge Mignani, Jean-Pierre Majoral, Maria Bryszewska, Tibor Hianik, Iveta Waczulikova
Biomedicines. 2021; 9(11): 1672
[Pubmed] | [DOI]
53 Biodegradable and Biocompatible Silatrane Polymers
Vladislav V. Istratov, Valerii A. Vasnev, Galy D. Markova
Molecules. 2021; 26(7): 1893
[Pubmed] | [DOI]
54 Controlled Anchoring of (Phenylureido)sulfonamide-Based Receptor Moieties: An Impact of Binding Site Multiplication on Complexation Properties
Karolína Salvadori, Alena Krupková, Lucie Cervenková Štastná, Monika Müllerová, Václav Eigner, Tomáš Strašák, Petra Curínová
Molecules. 2021; 26(18): 5670
[Pubmed] | [DOI]
55 Size and Structure of Empty and Filled Nanocontainer Based on Peptide Dendrimer with Histidine Spacers at Different pH
Valeriy V. Bezrodnyi, Sofia E. Mikhtaniuk, Oleg V. Shavykin, Igor M. Neelov, Nadezhda N. Sheveleva, Denis A. Markelov
Molecules. 2021; 26(21): 6552
[Pubmed] | [DOI]
56 Unconventional Approaches to Prepare Triazine-Based Liquid Crystal Dendrimers
Yao-Chih Lu, Hsiu-Fu Hsu, Long-Li Lai
Nanomaterials. 2021; 11(8): 2112
[Pubmed] | [DOI]
57 Considerable Improvement of Ursolic Acid Water Solubility by Its Encapsulation in Dendrimer Nanoparticles: Design, Synthesis and Physicochemical Characterization
Silvana Alfei, Anna Maria Schito, Guendalina Zuccari
Nanomaterials. 2021; 11(9): 2196
[Pubmed] | [DOI]
58 Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective
Alessandro Allegra, Mario Di Gioacchino, Alessandro Tonacci, Claudia Petrarca, Sebastiano Gangemi
Nanomaterials. 2021; 11(11): 2792
[Pubmed] | [DOI]
59 Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives
Sumaira Anjum, Sara Ishaque, Hijab Fatima, Wajiha Farooq, Christophe Hano, Bilal Haider Abbasi, Iram Anjum
Pharmaceuticals. 2021; 14(8): 707
[Pubmed] | [DOI]
60 Nano Based Approach for the Treatment of Neglected Tropical Diseases
Sureshbabu Ram Kumar Pandian, Theivendren Panneerselvam, Parasuraman Pavadai, Saravanan Govindaraj, Vigneshwaran Ravishankar, Ponnusamy Palanisamy, Muthukumar Sampath, Murugesan Sankaranarayanan, Selvaraj Kunjiappan
Frontiers in Nanotechnology. 2021; 3
[Pubmed] | [DOI]
61 Fetal Neuroprotective Strategies: Therapeutic Agents and Their Underlying Synaptic Pathways
Nada A. Elsayed, Theresa M. Boyer, Irina Burd
Frontiers in Synaptic Neuroscience. 2021; 13
[Pubmed] | [DOI]
62 Natural and Nanotechnology Based Treatment: An Alternative Approach to Psoriasis
Nishu Yadav, Rohan Aggarwal, Monika Targhotra, Prabhat K. Sahoo, Meenakshi K. Chauhan
Current Nanomedicine. 2021; 11(1): 21
[Pubmed] | [DOI]
63 Features of Self-Organization of Objects with a Fractal Structure of Dendritic Geometry
D. D. Ruzhitskaya, S. B. Ryzhikov, Yu. V. Ryzhikova
Moscow University Physics Bulletin. 2021; 76(5): 253
[Pubmed] | [DOI]
64 Evolutionary Timeline of Genetic Delivery and Gene Therapy
Natalie J. Holl, Han-Jung Lee, Yue-Wern Huang
Current Gene Therapy. 2021; 21(2): 89
[Pubmed] | [DOI]
65 Perfluorocarbons Therapeutics in Modern Cancer Nanotechnology for Hypoxiainduced Anti-tumor Therapy
Saurabh Satija, Prabal Sharma, Harpreet Kaur, Daljeet S. Dhanjal, Reena S. Chopra, Navneet Khurana, Manish Vyas, Neha Sharma, Murtaza M. Tambuwala, Hamid A. Bakshi, Nitin B. Charbe, Flavia C. Zacconi, Dinesh K. Chellappan, Kamal Dua, Meenu Mehta
Current Pharmaceutical Design. 2021; 27(43): 4376
[Pubmed] | [DOI]
66 Recent Advances in Herbal Nanomedicines for Cancer Treatment
Deepak Pradhan, Prativa Biswasroy, Amita Sahu, Dipak K. Sahu, Goutam Ghosh, Goutam Rath
Current Molecular Pharmacology. 2021; 14(3): 292
[Pubmed] | [DOI]
67 Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics
Rossana Cuciniello, Stefania Filosa, Stefania Crispi
Journal of Experimental & Clinical Cancer Research. 2021; 40(1)
[Pubmed] | [DOI]
68 Olanzapine Mesoporous Nanostructured Lipid Carrier: Optimization, Characterization, In Vivo Assessment, and Physiologically Based Pharmacokinetic Modeling
Hussein O. Ammar, Mahmoud M. Ghorab, Marwa S. Saleh, Amira M. Ghoneim
IEEE Transactions on NanoBioscience. 2021; 20(2): 166
[Pubmed] | [DOI]
69 Noyes-Whitney Dissolution Model-Based pH-Sensitive Slow Release of Paclitaxel (Taxol) from Human Hair-Derived Keratin Microparticle Carriers
V. W. Wimalasiri, S. P. Dunuweera, A. N. Dunuweera, R. M. G. Rajapakse, Victor Feitosa
BioMed Research International. 2021; 2021: 1
[Pubmed] | [DOI]
70 Dendrimers: A New Race of Pharmaceutical Nanocarriers
Pooja Mittal, Anjali Saharan, Ravinder Verma, Farag M. A. Altalbawy, Mohammed A. Alfaidi, Gaber El-Saber Batiha, Wahida Akter, Rupesh K. Gautam, Md. Sahab Uddin, Md. Sohanur Rahman, Mohammad Hassan Baig
BioMed Research International. 2021; 2021: 1
[Pubmed] | [DOI]
71 Toxicity of Nanoparticles in Biomedical Application: Nanotoxicology
Chukwuebuka Egbuna, Vijaykumar K. Parmar, Jaison Jeevanandam, Shahira M. Ezzat, Kingsley C. Patrick-Iwuanyanwu, Charles Oluwaseun Adetunji, Johra Khan, Eugene N. Onyeike, Chukwuemelie Zedech Uche, Muhammad Akram, Mervat S. Ibrahim, Nihal M. El Mahdy, Chinaza Godswill Awuchi, Kaliyaperumal Saravanan, Habibu Tijjani, Uchenna Estella Odoh, Mohammed Messaoudi, Jonathan C. Ifemeje, Michael C. Olisah, Nebechi Jane Ezeofor, Chukwudi Jude Chikwendu, Chinwe Gloria Ibeabuchi, You-Cheng Hseu
Journal of Toxicology. 2021; 2021: 1
[Pubmed] | [DOI]
72 Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature
Kah Min Yap, Mahendran Sekar, Shivkanya Fuloria, Yuan Seng Wu, Siew Hua Gan, Nur Najihah Izzati Mat Rani, Vetriselvan Subramaniyan, Chandrakant Kokare, Pei Teng Lum, M Yasmin Begum, Shankar Mani, Dhanalekshmi Unnikrishnan Meenakshi, Kathiresan V Sathasivam, Neeraj Kumar Fuloria
International Journal of Nanomedicine. 2021; Volume 16: 7891
[Pubmed] | [DOI]
73 Potential of Nanocarrier-Based Drug Delivery Systems for Brain Targeting: A Current Review of Literature
Badriyah Shadid Alotaibi, Manal Buabeid, Nihal Abdalla Ibrahim, Zelal Jaber Kharaba, Munazza Ijaz, Sobia Noreen, Ghulam Murtaza
International Journal of Nanomedicine. 2021; Volume 16: 7517
[Pubmed] | [DOI]
74 Chemical characterization (LC–MS–ESI), cytotoxic activity and intracellular localization of PAMAM G4 in leukemia cells
R. Flores-Mejía, M. J. Fragoso-Vázquez, L. G. Pérez-Blas, A. Parra-Barrera, S. S. Hernández-Castro, A. R. Estrada-Pérez, J. Rodrígues, E. Lara-Padilla, A. Ortiz-Morales, J. Correa-Basurto
Scientific Reports. 2021; 11(1)
[Pubmed] | [DOI]
75 Dendrimers in targeted drug delivery applications: a review of diseases and cancer
Ardhendu Kumar Mandal
International Journal of Polymeric Materials and Polymeric Biomaterials. 2021; 70(4): 287
[Pubmed] | [DOI]
76 Multi-sensitive curcumin-loaded nanomicelle based on ABC-CBA block copolymer for sustained drug delivery
Marzieh Kazemi, Mohsen Ashjari, Masoomeh Nazarabi
Drug Development and Industrial Pharmacy. 2021; 47(4): 552
[Pubmed] | [DOI]
77 Platelet activation by charged ligands and nanoparticles: platelet glycoprotein receptors as pattern recognition receptors
Samantha J. Montague, Pushpa Patel, Eleyna M. Martin, Alexandre Slater, Lourdes Garcia Quintanilla, Gina Perrella, Caroline Kardeby, Magdolna Nagy, Diego Mezzano, Paula M. Mendes, Steve P Watson
Platelets. 2021; : 1
[Pubmed] | [DOI]
78 Rational nanocarrier design towards clinical translation of cancer nanotherapy
Dandan Guo, Xiaotian Ji, Juntao Luo
Biomedical Materials. 2021; 16(3): 032005
[Pubmed] | [DOI]
79 Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview
Parusu Kavya Teja, Jinal Mithiya, Abhijeet S. Kate, Khemraj Bairwa, Siddheshwar K Chauthe
Phytomedicine. 2021; : 153890
[Pubmed] | [DOI]
80 Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma
Uday B. Kompella, Rachel R. Hartman, Madhoosudan A. Patil
Progress in Retinal and Eye Research. 2021; 82: 100901
[Pubmed] | [DOI]
81 Safe Polycationic Dendrimers as Potent Oral In Vivo Inhibitors of Mycobacterium tuberculosis: A New Therapy to Take Down Tuberculosis
Serge Mignani, Vishwa Deepak Tripathi, Dheerj Soam, Rama Pati Tripathi, Swetarka Das, Shriya Singh, Ramakrishna Gandikota, Regis Laurent, Andrii Karpus, Anne-Marie Caminade, Anke Steinmetz, Arunava Dasgupta, Kishore Kumar Srivastava, Jean-Pierre Majoral
Biomacromolecules. 2021; 22(6): 2659
[Pubmed] | [DOI]
82 Biodegradable Dendritic Polyglycerol Sulfate for the Delivery and Tumor Accumulation of Cytostatic Anticancer Drugs
Mariam Cherri, Magda Ferraro, Ehsan Mohammadifar, Elisa Quaas, Katharina Achazi, Kai Ludwig, Carsten Grötzinger, Michael Schirner, Rainer Haag
ACS Biomaterials Science & Engineering. 2021; 7(6): 2569
[Pubmed] | [DOI]
83 Supramolecular dendrimers based novel platforms for effective oral delivery of therapeutic moieties
Gasper Fernandes, Abhijeet Pandey, Sanjay Kulkarni, Sadhana P. Mutalik, Ajinkya Nitin Nikam, Raviraja N. Seetharam, Smita S. Kulkarni, Srinivas Mutalik
Journal of Drug Delivery Science and Technology. 2021; 64: 102647
[Pubmed] | [DOI]
84 RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy
Afsana Sheikh, Shadab Md, Prashant Kesharwani
Journal of Controlled Release. 2021; 340: 221
[Pubmed] | [DOI]
85 Protecting redesigned supercharged ferritin containers against protease by integration into acid-cleavable polyelectrolyte microgels
Made Budiarta, Wenjing Xu, Lukas Schubert, Maria Meledina, Alexander Meledin, Dominik Wöll, Andrij Pich, Tobias Beck
Journal of Colloid and Interface Science. 2021; 591: 451
[Pubmed] | [DOI]
86 Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization
Vivek Makwana, Jasmine Karanjia, Thomas Haselhorst, Shailendra Anoopkumar-Dukie, Santosh Rudrawar
International Journal of Pharmaceutics. 2021; 593: 120117
[Pubmed] | [DOI]
87 Graft hyper-branched dendrimer onto WS2 nanosheets modified Poly (N-Vinylcaprolactam) as a thermosensitive nanocarrier for Pioglitazone delivery using near-infrared radiation
Mohadeseh Sobhani, Alireza Zieglari, Elham Moniri, Homayon Ahmad Panahi, Maryam Daghighi Asli
International Journal of Pharmaceutics. 2021; 607: 120985
[Pubmed] | [DOI]
88 An insight into aptamer engineered dendrimer for cancer therapy
Afsana Sheikh, Prashant Kesharwani
European Polymer Journal. 2021; 159: 110746
[Pubmed] | [DOI]
89 Cutting-edge development in dendritic polymeric materials for biomedical and energy applications
Mohammad R. Thalji, Amal Amin Ibrahim, Gomaa A.M. Ali
European Polymer Journal. 2021; 160: 110770
[Pubmed] | [DOI]
90 Antibacterial toxicity of mesoporous silica nanoparticles with functional decoration of specific organic moieties
Min Ji Son, Sang-Wha Lee
Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2021; 630: 127612
[Pubmed] | [DOI]
91 Green surfactant-dendrimer aggreplexes: An ingenious way to launch dual attack on arch-enemy cancer
Nilesh Malavia, Rohan Ghadi, Kaushik Kuche, Tushar Date, Nallamothu Bhargavi, Dasharath Chaudhari, Rajan Swami, Parmeshwar B. Katare, Sanjay K. Banerjee, Sanyog Jain
Colloids and Surfaces B: Biointerfaces. 2021; 204: 111821
[Pubmed] | [DOI]
92 Material-based engineering of bacteria for cancer diagnosis and therapy
Tianzhong Li, Lingfeng Gao, Bin Zhang, Guohui Nie, Zhongjian Xie, Han Zhang, Hans Ågren
Applied Materials Today. 2021; 25: 101212
[Pubmed] | [DOI]
93 Covalent and noncovalent films made up of sulfonimide-based dendrimers
Julia Bondareva, Sergey Luchkin, Sarkis Dagesyan, Alexander Egorov, Stanislav Evlashin, Oleg Lukin
Applied Surface Science. 2021; 535: 146345
[Pubmed] | [DOI]
94 Interactions between PAMAM dendrimers and DOPC lipid multilayers: Membrane thinning and structural disorder
Laura J. Fox, Anna Slastanova, Nicolas Taylor, Magdalena Wlodek, Oier Bikondoa, Robert M. Richardson, Wuge H. Briscoe
Biochimica et Biophysica Acta (BBA) - General Subjects. 2021; 1865(4): 129542
[Pubmed] | [DOI]
95 Diseases and conditions that impact maternal and fetal health and the potential for nanomedicine therapies
Katherine M. Nelson, N'Dea Irvin-Choy, Matthew K. Hoffman, Jason P. Gleghorn, Emily S. Day
Advanced Drug Delivery Reviews. 2021; 170: 425
[Pubmed] | [DOI]
96 Advances in dendrimer-mediated targeted drug delivery to the brain
Rahul Gauro, Mukesh Nandave, Vineet Kumar Jain, Keerti Jain
Journal of Nanoparticle Research. 2021; 23(3)
[Pubmed] | [DOI]
97 Formulation, optimization, and in vitro characterization of omega-3-rich binary lipid carriers for curcumin delivery: in vitro evaluation of sustained release and its potential antioxidant behavior
Swathi Ganna, RajasekharaReddy Gutturu, Deva PrasadRaju Borelli, Kummara Madhusudana Rao, Koduru Mallikarjuna, John Sushma Nannepaga
Polymer Bulletin. 2021;
[Pubmed] | [DOI]
98 Newly isolated sporopollenin microcages from Cedrus libani and Pinus nigra as carrier for Oxaliplatin; xCELLigence RTCA-based release assay
Muhammad Mujtaba, Bahar Akyuz Yilmaz, Demet Cansaran-Duman, Lalehan Akyuz, Sevcan Yangin, Murat Kaya, Talip Çeter, Khalid Mahmood Khawar
Polymer Bulletin. 2021;
[Pubmed] | [DOI]
99 Intrinsic stimuli-responsive nanocarriers for smart drug delivery of antibacterial agents—An in-depth review of the last two decades
Nikita Devnarain, Nawras Osman, Victoria Oluwaseun Fasiku, Sifiso Makhathini, Mohammed Salih, Usri H. Ibrahim, Thirumala Govender
WIREs Nanomedicine and Nanobiotechnology. 2021; 13(1)
[Pubmed] | [DOI]
100 Nanocarrier-hydrogel composite delivery systems for precision drug release
Lauren E. Kass, Juliane Nguyen
WIREs Nanomedicine and Nanobiotechnology. 2021;
[Pubmed] | [DOI]
101 Parameters Influencing Gene Delivery Efficiency of PEGylated Chitosan Nanoparticles: Experimental and Modeling Approach
Nihal Olcay Dogan, Ugur Bozuyuk, Pelin Erkoc, Alp Can Karacakol, Ahmet Cingoz, Fidan Seker-Polat, Muhammad Anwaar Nazeer, Metin Sitti, Tugba Bagci-Onder, Seda Kizilel
Advanced NanoBiomed Research. 2021; : 2100033
[Pubmed] | [DOI]
102 Increased Valency Improves Inhibitory Activity of Peptides Targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Benjamin J. Tombling, Carmen Lammi, Carlotta Bollati, Anna Anoldi, David J. Craik, Conan K. Wang
ChemBioChem. 2021; 22(12): 2154
[Pubmed] | [DOI]
103 Preparation of Amine- and Disulfide-Containing PAMAM-Based Dendrons for the Functionalization of Hydroxylated Surfaces: XPS as Structural Sensor
Herlys Viltres, Oscar F. Odio, Mark. C. Biesinger, Gala Montiel, Raúl Borja, Edilso Reguera
ChemistrySelect. 2020; 5(16): 4875
[Pubmed] | [DOI]
104 Solvent-Assisted [(Glycine)-(MP-SiO 2 NPs)] Aggregate for Drug Loading and Cancer Therapy
Chander Amgoth, Rompivalasa Santhosh, Tirupathi Malavath, Avinash Singh, Banavoth Murali, Guping Tang
ChemistrySelect. 2020; 5(27): 8221
[Pubmed] | [DOI]
105 Thrombolytic Agents: Nanocarriers in Controlled Release
Soodabeh Hassanpour, Han-Jun Kim, Arezoo Saadati, Peyton Tebon, Chengbin Xue, Floor W. Dolder, Jai Thakor, Behzad Baradaran, Jafar Mosafer, Amir Baghbanzadeh, Natan Roberto Barros, Mahmoud Hashemzaei, Kang?Ju Lee, Junmin Lee, Shiming Zhang, Wujin Sun, Hyun-Jong Cho, Samad Ahadian, Nureddin Ashammakhi, Mehmet R. Dokmeci, Ahad Mokhtarzadeh, Ali Khademhosseini
Small. 2020; 16(40): 2001647
[Pubmed] | [DOI]
106 Transdermal theranostics
Aung Than, Ping Zan, Peng Chen
View. 2020; 1(2)
[Pubmed] | [DOI]
107 Recent developments in the use of organic–inorganic nanohybrids for drug delivery
Danushika C. Manatunga, V. Umayangana Godakanda, Rohini M. Silva, K. M. Nalin Silva
WIREs Nanomedicine and Nanobiotechnology. 2020; 12(3)
[Pubmed] | [DOI]
108 Nanoporous Anodic Alumina Platforms for Drug Delivery Applications: Recent Advances and Perspective
Pankaj Kapruwan, Josep Ferré-Borrull, Lluis F. Marsal
Advanced Materials Interfaces. 2020; 7(22): 2001133
[Pubmed] | [DOI]
109 Nanomedicine Revisited: Next Generation Therapies for Brain Cancer
Adip G. Bhargav, Sujan K. Mondal, Cesar A. Garcia, Jordan J. Green, Alfredo Quiñones-Hinojosa
Advanced Therapeutics. 2020; 3(10): 2000118
[Pubmed] | [DOI]
110 Neuroprotective Effect of New Nanochelating-Based Nano Complex, ALZc3, Against Aß (1–42)-Induced Toxicity in Rat: a Comparison with Memantine
Ramin Karimi-Sales, Mehrafarin Ashiri, Maryam Hafizi, Somayeh Kalanaky, Amir Hossein Maghsoudi, Saideh Fakharzadeh, Nader Maghsoudi, Mohammad Hassan Nazaran
Pharmaceutical Research. 2020; 37(3)
[Pubmed] | [DOI]
111 Sacrificial sulphonated polystyrene template-assisted synthesis of mesoporous hollow core-shell silica nanoparticles for drug-delivery application
Deepika Doddamani, Jagadeeshbabu PonnanEttiyappan
Bulletin of Materials Science. 2020; 43(1)
[Pubmed] | [DOI]
112 Polyamidoamine dendrimer–digoxin impregnated PVC film in the fingerprint detection of herbs’ essential oil coupled to gas chromatography–mass spectrometry
Eskandar Moghimipour, Zahra Ramezani, Somayeh Handali, Ahmad Babapoor
Journal of the Iranian Chemical Society. 2020; 17(10): 2545
[Pubmed] | [DOI]
113 Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics
Elham Hatami, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2020; 1874(1): 188381
[Pubmed] | [DOI]
114 Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent
Lukasz Uram, Joanna Markowicz, Maria Misiorek, Aleksandra Filipowicz-Rachwal, Stanislaw Wolowiec, Elzbieta Walajtys-Rode
European Journal of Pharmaceutical Sciences. 2020; 152: 105439
[Pubmed] | [DOI]
115 The interaction of nanostructured antimicrobials with biological systems: Cellular uptake, trafficking and potential toxicity
Adriano Brandelli
Food Science and Human Wellness. 2020; 9(1): 8
[Pubmed] | [DOI]
116 Dendrimers in the context of nanomedicine
Ana Paula Dias, Soraya da Silva Santos, João Vitor da Silva, Roberto Parise-Filho, Elizabeth Igne Ferreira, Omar El Seoud, Jeanine Giarolla
International Journal of Pharmaceutics. 2020; 573: 118814
[Pubmed] | [DOI]
117 Influence cationic and anionic PAMAM dendrimers of low generation on selected hemostatic parameters in vitro
Roza Aisina, Liliya Mukhametova, Elizaveta Ivanova
Materials Science and Engineering: C. 2020; 109: 110605
[Pubmed] | [DOI]
118 Dendrimer assisted dye-removal: A critical review of adsorption and catalytic degradation for wastewater treatment
Muhammad B. Wazir, Muhammad Daud, Faheem Ali, Mamdouh A. Al-Harthi
Journal of Molecular Liquids. 2020; 315: 113775
[Pubmed] | [DOI]
119 Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients
Paul L. Chariou, Oscar A. Ortega-Rivera, Nicole F. Steinmetz
ACS Nano. 2020; 14(3): 2678
[Pubmed] | [DOI]
120 Lenalidomide (LENA) Hybrid Gold Complex Nanoparticles: Synthesis, Physicochemical Evaluation, and Perspectives in Nanomedicine
Celia Arib, Jolanda Spadavecchia
ACS Omega. 2020; 5(44): 28483
[Pubmed] | [DOI]
121 Stimulus-responsive sequential release systems for drug and gene delivery
Sepideh Ahmadi, Navid Rabiee, Mojtaba Bagherzadeh, Faranak Elmi, Yousef Fatahi, Fatemeh Farjadian, Nafiseh Baheiraei, Behzad Nasseri, Mohammad Rabiee, Niloufar Tavakoli Dastjerd, Ali Valibeik, Mahdi Karimi, Michael R. Hamblin
Nano Today. 2020; 34: 100914
[Pubmed] | [DOI]
122 Nanocarriers for effective nutraceutical delivery to the brain
Rugmani Meenambal, M.M. Srinivas Bharath
Neurochemistry International. 2020; 140: 104851
[Pubmed] | [DOI]
123 Influence of Ultrasound and Magnetic Field Treatment Time on Carcinoma Cell Inhibition with Drug Carriers: An in Vitro Study
Somoshree Sengupta, Chandra Khatua, Aniruddha Pal, Subhadip Bodhak, Vamsi Krishna Balla
Ultrasound in Medicine & Biology. 2020; 46(10): 2752
[Pubmed] | [DOI]
124 Dendrimers toward Translational Nanotherapeutics: Concise Key Step Analysis
Serge Mignani, Xiangyang Shi, João Rodrigues, René Roy, Ángeles Muñoz-Fernández, Valentin Ceña, Jean-Pierre Majoral
Bioconjugate Chemistry. 2020; 31(9): 2060
[Pubmed] | [DOI]
125 Biosensing strategies based on organic-scaffolded metal nanoclusters for ultrasensitive detection of tumor markers
Leila Farzin, Mojtaba Shamsipur, Leila Samandari, Sodeh Sadjadi, Shahab Sheibani
Talanta. 2020; 214: 120886
[Pubmed] | [DOI]
126 Leveraging Electrostatic Interactions for Drug Delivery to the Joint
Shreedevi Kumar, Blanka Sharma
Bioelectricity. 2020; 2(2): 82
[Pubmed] | [DOI]
127 Emerging trends in nanomedicine for topical delivery in skin disorders: Current and translational approaches
Parijat Pandey, Saurabh Satija, Ridhima Wadhwa, Meenu Mehta, Deepika Purohit, Gaurav Gupta, Parteek Prasher, Dinesh K. Chellappan, Rajendra Awasthi, Harish Dureja, Kamal Dua
Dermatologic Therapy. 2020; 33(3)
[Pubmed] | [DOI]
128 The Nature of the Inhibitory Action of Anionic Polyamidoamine Dendrimers of Generation 1.5–3.5 on the Activity of the Fibrinolytic System
R. B. Aisina, L. I. Mukhametova, E. M. Ivanova
Russian Journal of Bioorganic Chemistry. 2020; 46(5): 787
[Pubmed] | [DOI]
129 Targeting Tumour Metastasis: The Emerging Role of Nanotechnology
Sarah Visentin, Mirela Sedic, Sandra Kraljevic Pavelic, Krešimir Pavelic
Current Medicinal Chemistry. 2020; 27(8): 1367
[Pubmed] | [DOI]
130 Recent Progresses in Organic-Inorganic Nano Technological Platforms for Cancer Therapeutics
Sanjay Kumar, Anchal Singhal, Uma Narang, Sweta Mishra, Pratibha Kumari
Current Medicinal Chemistry. 2020; 27(35): 6015
[Pubmed] | [DOI]
131 Dendrimer nanoparticles for colorectal cancer applications
M. R. Carvalho, R. L. Reis, J. M. Oliveira
Journal of Materials Chemistry B. 2020; 8(6): 1128
[Pubmed] | [DOI]
132

PAMAM Dendrimer Nanomolecules Utilized as Drug Delivery Systems for Potential Treatment of Glioblastoma: A Systematic Review

Michael Fana, John Gallien, Bhairavi Srinageshwar, Gary L. Dunbar, Julien Rossignol
International Journal of Nanomedicine. 2020; Volume 15: 2789
[Pubmed] | [DOI]
133 Trends in Nanomedicines for Cancer Treatment
Tatielle do Nascimento, Adriane R. Todeschini, Ralph Santos-Oliveira, Mariana S. de Souza de Bustamante Monteiro, Vilênia T. de Souza, Eduardo Ricci-Júnior
Current Pharmaceutical Design. 2020; 26(29): 3579
[Pubmed] | [DOI]
134 Advancing of Cellular Signaling Pathways in Respiratory Diseases Using Nanocarrier Based Drug Delivery Systems
Meenu Mehta, Daljeet Singh Dhanjal, Saurabh Satija, Ridhima Wadhwa, Keshav Raj Paudel, Dinesh Kumar Chellappan, Shiva Mohammad, Mehra Haghi, Philip M. Hansbro, Kamal Dua
Current Pharmaceutical Design. 2020; 26(42): 5380
[Pubmed] | [DOI]
135 Pressurized DNA state inside herpes capsids—A novel antiviral target
Alberto Brandariz-Nuñez, Scott J. Robinson, Alex Evilevitch, Donna Neumann
PLOS Pathogens. 2020; 16(7): e1008604
[Pubmed] | [DOI]
136 Nanomedicine: A Promising Avenue for the Development of Effective Therapy for Breast Cancer
Ali Sartaj, Sanjula Baboota, Javed Ali
Current Cancer Drug Targets. 2020; 20(8): 603
[Pubmed] | [DOI]
137 Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment
Archu Singh, Sadat Shafi, Tanya Upadhyay, Abul Kalam Najmi, Kanchan Kohli, Faheem Hyder Pottoo
Current Topics in Medicinal Chemistry. 2020; 20(20): 1839
[Pubmed] | [DOI]
138 Understanding the Pharmaceutical Aspects of Dendrimers for the Delivery of Anticancer Drugs
Sunil Kumar Dubey, Shubham Salunkhe, Mukta Agrawal, Maithili Kali, Gautam Singhvi, Sanjay Tiwari, Swarnlata Saraf, Shailendra Saraf, Amit Alexander
Current Drug Targets. 2020; 21(6): 528
[Pubmed] | [DOI]
139 Polyester-Based Dendrimer Nanoparticles Combined with Etoposide Have an Improved Cytotoxic and Pro-Oxidant Effect on Human Neuroblastoma Cells
Silvana Alfei, Barbara Marengo, Cinzia Domenicotti
Antioxidants. 2020; 9(1): 50
[Pubmed] | [DOI]
140 Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems
Shi Su, Peter M. Kang
Pharmaceutics. 2020; 12(9): 837
[Pubmed] | [DOI]
141 Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management
Sathishbabu Paranthaman, Meghana Goravinahalli Shivananjegowda, Manohar Mahadev, Afrasim Moin, Shivakumar Hagalavadi Nanjappa, Nandakumar Dalavaikodihalli Nanjaiyah, Saravana Babu Chidambaram, Devegowda Vishakante Gowda
Pharmaceutics. 2020; 12(12): 1198
[Pubmed] | [DOI]
142 Photosensitive Supramolecular Micelle-Mediated Cellular Uptake of Anticancer Drugs Enhances the Efficiency of Chemotherapy
Yihalem Abebe Alemayehu, Wen-Lu Fan, Fasih Bintang Ilhami, Chih-Wei Chiu, Duu-Jong Lee, Chih-Chia Cheng
International Journal of Molecular Sciences. 2020; 21(13): 4677
[Pubmed] | [DOI]
143 Stimuli-Responsive Materials for Tissue Engineering and Drug Delivery
Sofia Municoy, María I. Álvarez Echazú, Pablo E. Antezana, Juan M. Galdopórpora, Christian Olivetti, Andrea M. Mebert, María L. Foglia, María V. Tuttolomondo, Gisela S. Alvarez, John G. Hardy, Martin F. Desimone
International Journal of Molecular Sciences. 2020; 21(13): 4724
[Pubmed] | [DOI]
144 Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections
Arturo Sánchez, Susana P. Mejía, Jahir Orozco
Molecules. 2020; 25(16): 3760
[Pubmed] | [DOI]
145 Applications and Limitations of Dendrimers in Biomedicine
Adriana Aurelia Chis, Carmen Dobrea, Claudiu Morgovan, Anca Maria Arseniu, Luca Liviu Rus, Anca Butuca, Anca Maria Juncan, Maria Totan, Andreea Loredana Vonica-Tincu, Gabriela Cormos, Andrei Catalin Muntean, Maria Lucia Muresan, Felicia Gabriela Gligor, Adina Frum
Molecules. 2020; 25(17): 3982
[Pubmed] | [DOI]
146 Synthesis, Internalization and Visualization of N-(4-Carbomethoxy) Pyrrolidone Terminated PAMAM [G5:G3-TREN] Tecto(dendrimers) in Mammalian Cells
Maciej Studzian, Paula Dzialak, Lukasz Pulaski, David M. Hedstrand, Donald A. Tomalia, Barbara Klajnert-Maculewicz
Molecules. 2020; 25(19): 4406
[Pubmed] | [DOI]
147 Dendrimers as Modulators of Brain Cells
Dusica Maysinger, Qiaochu Zhang, Ashok Kakkar
Molecules. 2020; 25(19): 4489
[Pubmed] | [DOI]
148 Comparison of Structure and Local Dynamics of Two Peptide Dendrimers with the Same Backbone but with Different Side Groups in Their Spacers
Sofia Mikhtaniuk, Valeriy Bezrodnyi, Oleg Shavykin, Igor Neelov, Nadezhda Sheveleva, Anastasia Penkova, Denis Markelov
Polymers. 2020; 12(8): 1657
[Pubmed] | [DOI]
149 Sulfonimide-Based Dendrimers: Progress in Synthesis, Characterization, and Potential Applications
Julia V. Bondareva, Stanislav A. Evlashin, Oleg V. Lukin
Polymers. 2020; 12(12): 2987
[Pubmed] | [DOI]
150 Dendritic polyglycerols are modulators of microglia-astrocyte crosstalk
Dusica Maysinger, Mélanie Lalancette-Hébert, Jeff Ji, Katherine Jabbour, Jens Dernedde, Kim Silberreis, Rainer Haag, Jasna Kriz
Future Neurology. 2019; 14(4): FNL31
[Pubmed] | [DOI]
151 Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery
Areen Alshweiat, Rita Ambrus, IIdikó Csóka
Current Medicinal Chemistry. 2019; 26(35): 6459
[Pubmed] | [DOI]
152 Direct Surface Functionalization of Cellulose Nanocrystals with Hyperbranched Polymers through the Anionic Polymerization for pH-Responsive Intracellular Drug Delivery
Weimin Wan, Hui Ouyang, Wei Long, Wenfeng Yan, Mingzhen He, Hongye Huang, Shilin Yang, Xiaoyong Zhang, Yulin Feng, Yen Wei
ACS Sustainable Chemistry & Engineering. 2019; 7(23): 19202
[Pubmed] | [DOI]
153 Enhanced Delivery of Plasmid DNA to Skeletal Muscle Cells using a DLC8-Binding Peptide and ASSLNIA-Modified PAMAM Dendrimer
Samuel D. Jativa, Neelanshu Thapar, David Broyles, Emre Dikici, Pirouz Daftarian, Joaquín J. Jiménez, Sylvia Daunert, Sapna K. Deo
Molecular Pharmaceutics. 2019; 16(6): 2376
[Pubmed] | [DOI]
154 Recoverable Bismuth-Based Microrobots: Capture, Transport, and On-Demand Release of Heavy Metals and an Anticancer Drug in Confined Spaces
Seyyed Mohsen Beladi-Mousavi, Bahareh Khezri, Ludmila Krejcová, Zbynek Heger, Zdenek Sofer, Adrian C. Fisher, Martin Pumera
ACS Applied Materials & Interfaces. 2019; 11(14): 13359
[Pubmed] | [DOI]
155 Preparation and Evaluation of Antimicrobial Hyperbranched Emulsifiers for Waterborne Coatings
Pei Zhao, Francesco Mecozzi, Stefan Wessel, Bram Fieten, Marianne Driesse, Willem Woudstra, Henk J. Busscher, Henny C. van der Mei, Ton J. A. Loontjens
Langmuir. 2019; 35(17): 5779
[Pubmed] | [DOI]
156 Dendrimer-Enabled Therapeutic Antisense Delivery Systems as Innovation in Medicine
Serge Mignani, Xiangyang Shi, Maria Zablocka, Jean-Pierre Majoral
Bioconjugate Chemistry. 2019; 30(7): 1938
[Pubmed] | [DOI]
157 Polymeric and lipid-based drug delivery systems for treatment of glioblastoma multiforme
Ramesh Duwa, Fakhrossadat Emami, Sooyeun Lee, Jee-Heon Jeong, Simmyung Yook
Journal of Industrial and Engineering Chemistry. 2019; 79: 261
[Pubmed] | [DOI]
158 Multifunctional hyaluronate – nanoparticle hybrid systems for diagnostic, therapeutic and theranostic applications
Hyemin Kim, Yoonsang Park, Molly M. Stevens, Woosung Kwon, Sei Kwang Hahn
Journal of Controlled Release. 2019; 303: 55
[Pubmed] | [DOI]
159 Interactions between microbiome and lungs: Paving new paths for microbiome based bio-engineered drug delivery systems in chronic respiratory diseases
Dinesh Kumar Chellappan, Quinnie Ling Sze Ning, Sandra Khoo Su Min, Saw Yan Bin, Pang Jia Chern, Tan Pei Shi, Sylvia Wong Ee Mei, Tan Hui Yee, Ong Jing Qi, Lakshmi Thangavelu, S. Rajeshkumar, Poonam Negi, Jestin Chellian, Ridhima Wadhwa, Gaurav Gupta, Trudi Collet, Philip M. Hansbro, Kamal Dua
Chemico-Biological Interactions. 2019; 310: 108732
[Pubmed] | [DOI]
160 Pyrrolidone Modification Prevents PAMAM Dendrimers from Activation of Pro-Inflammatory Signaling Pathways in Human Monocytes
Anna Janaszewska, Michal Gorzkiewicz, Mario Ficker, Johannes Fabritius Petersen, Valentina Paolucci, Jørn Bolstad Christensen, Barbara Klajnert-Maculewicz
Molecular Pharmaceutics. 2018; 15(1): 12
[Pubmed] | [DOI]
161 Bacterial Resistance and Prostate Cancer Susceptibility Toward Metal-Ion-doped DNA Complexes
Srivithya Vellampatti, Gopalakrishnan Chandrasekaran, Sekhar Babu Mitta, Sreekantha Reddy Dugasani, Vinoth-Kumar Lakshmanan, Sung Ha Park
ACS Applied Materials & Interfaces. 2018; 10(51): 44290
[Pubmed] | [DOI]
162 In Vitro Carcinoma Treatment Using Magnetic Nanocarriers under Ultrasound and Magnetic Fields
Somoshree Sengupta, Chandra Khatua, Vamsi K. Balla
ACS Omega. 2018; 3(5): 5459
[Pubmed] | [DOI]
163 Removal of heavy metals and organic pollutants from water using dendritic polymers based adsorbents: A critical review
Muhammad Sajid,Mazen Khaled Nazal,Mazen Khaled Ihsanullah,Nadeem Baig,Abdalghaffar Mohammad Osman
Separation and Purification Technology. 2018; 191: 400
[Pubmed] | [DOI]
164 Novel advances in targeted drug delivery
Kivilcim Öztürk, Hakan Eroglu, Sema Çalis
Journal of Drug Targeting. 2018; 26(8): 633
[Pubmed] | [DOI]
165 Screening of the structural, topological, and electronic properties of the functionalized Graphene nanosheets as potential Tegafur anticancer drug carriers using DFT method
Mahnaz Shahabi,Heidar Raissi
Journal of Biomolecular Structure and Dynamics. 2017; : 1
[Pubmed] | [DOI]
166 Dendrimers for ocular drug delivery
Michael G. Lancina,Hu Yang
Canadian Journal of Chemistry. 2017; : 1
[Pubmed] | [DOI]
167 Gd3+-Asparagine-Anionic Linear Globular Dendrimer Second-Generation G2 Complexes: Novel Nanobiohybrid Theranostics
Nasim Hashempour Alamdari,Mahmood Alaei-Beirami,Seyed Ataollah Sadat Shandiz,Hadi Hejazinia,Rahimeh Rasouli,Mostafa Saffari,Seyed Esmaeil Sadat Ebrahimi,Artin Assadi,Mehdi Shafiee Ardestani
Contrast Media & Molecular Imaging. 2017; 2017: 1
[Pubmed] | [DOI]
168 Evaluation of G2 Citric Acid-Based Dendrimer as an Adjuvant in Veterinary Rabies Vaccine
Vahid Asgary,Alireza Shoari,Majid Afshar Moayad,Mehdi Shafiee Ardestani,Razieh Bigdeli,Leila Ghazizadeh,Mohammad Sadeq Khosravy,Erfan Panahnejad,Alireza Janani,Rouzbeh Bashar,Maliheh Abedi,Reza Ahangari Cohan
Viral Immunology. 2017;
[Pubmed] | [DOI]
169 Biocompatible nanomaterials based on dendrimers, hydrogels and hydrogel nanocomposites for use in biomedicine
Cuu Khoa Nguyen,Ngoc Quyen Tran,Thi Phuong Nguyen,Dai Hai Nguyen
Advances in Natural Sciences: Nanoscience and Nanotechnology. 2017; 8(1): 015001
[Pubmed] | [DOI]
170 Legionella Pneumophila and Dendrimers-Mediated Antisense Therapy
Roghiyeh Pashaei-Asl,Khodadad Khodadadi,Fatima Pashaei-Asl,Gholamreza Haqshenas,Nasser Ahmadian,Maryam Pashaiasl,Reza Hajihosseini Baghdadabadi
Advanced Pharmaceutical Bulletin. 2017; 7(2): 179
[Pubmed] | [DOI]
171 Functionalized materials for multistage platforms in the oral delivery of biopharmaceuticals
Francisca Araújo,José das Neves,João Pedro Martins,Pedro L. Granja,Hélder A. Santos,Bruno Sarmento
Progress in Materials Science. 2017; 89: 306
[Pubmed] | [DOI]
172 Stabilization of polypropylene-based materials via molecular retention with hyperbranched polymer
Akanksha Matta,Ikki Katada,Junji Kawazoe,Patchanee Chammingkwan,Minoru Terano,Toshiaki Taniike
Polymer Degradation and Stability. 2017; 142: 50
[Pubmed] | [DOI]
173 Fast Dissolving Dendrimer Nanofiber Mats as Alternative to Eye Drops for More Efficient Antiglaucoma Drug Delivery
Michael G. Lancina,Sudha Singh,Uday B. Kompella,Shahid Husain,Hu Yang
ACS Biomaterials Science & Engineering. 2017;
[Pubmed] | [DOI]
174 Therapeutic Role and Drug Delivery Potential of Neuroinflammation as a Target in Neurodegenerative Disorders
Abhijeet Singh,Ankit Chokriwal,Madan Mohan Sharma,Devendra Jain,Juhi Saxena,Bjorn John Stephen
ACS Chemical Neuroscience. 2017; 8(8): 1645
[Pubmed] | [DOI]
175 Carbon Nanotube as a Tool for Fighting Cancer
Edson José Comparetti,Valber de Albuquerque Pedrosa,Ramon Kaneno
Bioconjugate Chemistry. 2017;
[Pubmed] | [DOI]
176 Activated microglia targeting dendrimer-minocycline conjugate as therapeutics for neuroinflammation
Rishi Sharma,Soo-Young Kim,Anjali Sharma,Zhi Zhang,Siva Pramodh Kambhampati,Sujatha Kannan,Rangaramanujam M Kannan
Bioconjugate Chemistry. 2017;
[Pubmed] | [DOI]
177 New Modalities for Challenging Targets in Drug Discovery
Eric Valeur,Stéphanie M. Guéret,Hélène Adihou,Ranganath Gopalakrishnan,Malin Lemurell,Herbert Waldmann,Tom N. Grossmann,Alleyn T. Plowright
Angewandte Chemie International Edition. 2017;
[Pubmed] | [DOI]
178 Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Mayur M. Patel,Bhoomika M. Patel
CNS Drugs. 2017; 31(2): 109
[Pubmed] | [DOI]
179 Aptamer-targeted delivery of Bcl-xL shRNA using alkyl modified PAMAM dendrimers into lung cancer cells
Sara Ayatollahi,Zahra Salmasi,Maryam Hashemi,Saeedeh Askarian,Reza Kazemi Oskuee,Khalil Abnous,Mohammad Ramezani
The International Journal of Biochemistry & Cell Biology. 2017;
[Pubmed] | [DOI]
180 Positioning metal-organic framework nanoparticles within the context of drug delivery – A comparison with mesoporous silica nanoparticles and dendrimers
Stefan Wuttke,Marjorie Lismont,Alberto Escudero,Bunyarat Rungtaweevoranit,Wolfgang J. Parak
Biomaterials. 2017;
[Pubmed] | [DOI]
181 Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases
Anindita Chowdhury,Selvaraj Kunjiappan,Theivendren Panneerselvam,Balasubramanian Somasundaram,Chiranjib Bhattacharjee
International Nano Letters. 2017;
[Pubmed] | [DOI]
182 Relation between biophysical properties of nanostructures and their toxicity on zebrafish
C. S. Martinez,D. E. Igartúa,M. N. Calienni,D. A. Feas,M. Siri,J. Montanari,N. S. Chiaramoni,S. del V. Alonso,M. J. Prieto
Biophysical Reviews. 2017;
[Pubmed] | [DOI]
183 Neue Modalitäten für schwierige Zielstrukturen in der Wirkstoffentwicklung
Eric Valeur,Stéphanie M. Guéret,Hélène Adihou,Ranganath Gopalakrishnan,Malin Lemurell,Herbert Waldmann,Tom N. Grossmann,Alleyn T. Plowright
Angewandte Chemie. 2017;
[Pubmed] | [DOI]
184 Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases
Christos Tapeinos,Matteo Battaglini,Gianni Ciofani
Journal of Controlled Release. 2017; 264: 306
[Pubmed] | [DOI]
185 Carbosilane metallodendrimers based on copper (II) complexes: Synthesis, EPR characterization and anticancer activity
Natalia Sanz del Olmo,Marta Maroto-Díaz,Rafael Gómez,Paula Ortega,Michela Cangiotti,M. Francesca Ottaviani,F. Javier de la Mata
Journal of Inorganic Biochemistry. 2017; 177: 211
[Pubmed] | [DOI]
186 Perspectives on dendritic architectures and their biological applications: From core to cell
Valikala Viswanath,Kannappan Santhakumar
Journal of Photochemistry and Photobiology B: Biology. 2017; 173: 61
[Pubmed] | [DOI]
187 Influence of the doxorubicin conjugated PAMAM dendrimer surface charge on cytotoxic effects and intracellular trafficking routes in tumor cells
E. Nikolskaya,N. Yabbarov,O. Zhunina,O. Tereshenko,M. Mollaev,M. Faustova,I. Zamulaeva,E. Severin
Materials Today: Proceedings. 2017; 4(7): 6849
[Pubmed] | [DOI]
188 Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers
Kivilcim Öztürk,Günes Esendagli,Mustafa Ulvi Gürbüz,Metin Tülü,Sema Çalis
International Journal of Pharmaceutics. 2017; 517(1-2): 157
[Pubmed] | [DOI]
189 A Prominent Anchoring Effect on the Kinetic Control of Drug Release from Mesoporous Silica Nanoparticles (MSNs)
Anh-Vy Tran,Sang-Wha Lee
Journal of Colloid and Interface Science. 2017;
[Pubmed] | [DOI]
190 Dendritic polymers for dermal drug delivery
Kaushalkumar Dave,Venkata Vamsi Krishna Venuganti
Therapeutic Delivery. 2017; 8(12): 1077
[Pubmed] | [DOI]
191 Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy
Livia Palmerston Mendes,Jiayi Pan,Vladimir Torchilin
Molecules. 2017; 22(9): 1401
[Pubmed] | [DOI]
192 Polymers in Drug Delivery
Apurva Srivastava,Tejaswita Yadav,Soumya Sharma,Anjali Nayak,Akanksha Akanksha Kumari,Nidhi Mishra
Journal of Biosciences and Medicines. 2016; 04(01): 69
[Pubmed] | [DOI]
193 Application of nanomedicine for crossing the blood–brain barrier: Theranostic opportunities in multiple sclerosis
Ghasem Ghalamfarsa,Mohammad Hojjat-Farsangi,Mousa Mohammadnia-Afrouzi,Enayat Anvari,Shohreh Farhadi,Mehdi Yousefi,Farhad Jadidi-Niaragh
Journal of Immunotoxicology. 2016; : 1
[Pubmed] | [DOI]
194 Dendrimers in anticancer drug delivery: mechanism of interaction of drug and dendrimers
Jaspreet Singh,Keerti Jain,Neelesh Kumar Mehra,N. K. Jain
Artificial Cells, Nanomedicine, and Biotechnology. 2016; : 1
[Pubmed] | [DOI]
195 Dendrimer-based nanoparticles for potential personalized therapy in chronic lymphocytic leukemia: targeting the BCR-Signaling Pathway
Ida Franiak-Pietryga,Henryk Maciejewski,Kinga Ostrowska,Dietmar Appelhans,Brigitte Voit,Malgorzata Misiewicz,Pawel Kowalczyk,Maria Bryszewska,Maciej Borowiec
International Journal of Biological Macromolecules. 2016;
[Pubmed] | [DOI]
196 Peptide-Decorated Dendrimers and Their Bioapplications
Jingjing Wan,Paul F. Alewood
Angewandte Chemie International Edition. 2016; : n/a
[Pubmed] | [DOI]
197 Peptide-Based Multicomponent Oligonucleotide Delivery Systems: Optimisation of Poly-l-lysine Dendrons for Plasmid DNA Delivery
Khairul A. Kamaruzaman,Peter M. Moyle,Istvan Toth
International Journal of Peptide Research and Therapeutics. 2016;
[Pubmed] | [DOI]
198 Mit Peptiden dekorierte Dendrimere und ihre biotechnologische Nutzung
Jingjing Wan,Paul F. Alewood
Angewandte Chemie. 2016; : n/a
[Pubmed] | [DOI]
199 Therapeutic Potential of Foldamers: From Chemical Biology Tools to Drug Candidates?
Ranganath Gopalakrishnan,Andrey I. Frolov,Laurent Knerr,William J. Drury,Eric Valeur
Journal of Medicinal Chemistry. 2016;
[Pubmed] | [DOI]
200 IL-6 Antibody and RGD Peptide Conjugated Poly(amidoamine) Dendrimer for Targeted Drug Delivery of HeLa Cells
Shewaye Lakew Mekuria,Tilahun Ayane Debele,Hsiao-Ying Chou,Hsieh-Chih Tsai
The Journal of Physical Chemistry B. 2016; 120(1): 123
[Pubmed] | [DOI]
201 Effect of Several HIV Antigens Simultaneously Loaded with G2-NN16 Carbosilane Dendrimer in the Cell Uptake and Functionality of Human Dendritic Cells
Daniel Sepúlveda-Crespo,Enrique Vacas-Córdoba,Valeria Márquez-Miranda,Ingrid Araya-Durán,Rafael Gómez,Francisco Javier de la Mata,Fernando Danilo González-Nilo,M Ángeles Muñoz-Fernández
Bioconjugate Chemistry. 2016; 27(12): 2844
[Pubmed] | [DOI]
202 From Diagnosis to Treatment
Christopher S. Digesu,Sophie C. Hofferberth,Mark W. Grinstaff,Yolonda L. Colson
Thoracic Surgery Clinics. 2016; 26(2): 215
[Pubmed] | [DOI]
203 Nanocarriers based delivery of nutraceuticals for cancer prevention and treatment: A review of recent research developments
Divya Arora,Sundeep Jaglan
Trends in Food Science & Technology. 2016; 54: 114
[Pubmed] | [DOI]
204 Alternative approaches for the treatment of airway diseases: focus on nanoparticle medicine
E. Ratemi,A. Sultana Shaik,A. Al Faraj,R. Halwani
Clinical & Experimental Allergy. 2016; 46(8): 1033
[Pubmed] | [DOI]
205 Recent perspectives on the delivery of biologics to back of the eye
Mary Joseph,Hoang M. Trinh,Kishore Cholkar,Dhananjay Pal,Ashim K. Mitra
Expert Opinion on Drug Delivery. 2016; : 1
[Pubmed] | [DOI]
206 PAMAM dendrimer based targeted nano-carrier for bio-imaging and therapeutic agents
Shewaye Lakew Mekuria,Tilahun Ayane Debele,Hsieh-Chih Tsai
RSC Adv.. 2016; 6(68): 63761
[Pubmed] | [DOI]
207 Multifunctional nanoparticles: recent progress in cancer therapeutics
G. Seeta Rama Raju,Leah Benton,E. Pavitra,Jae Su Yu
Chem. Commun.. 2015; 51(68): 13248
[Pubmed] | [DOI]
208 Polyanionic carbosilane dendrimer-conjugated antiviral drugs as efficient microbicides: Recent trends and developments in HIV treatment/therapy
Daniel Sepúlveda-Crespo,Rafael Gómez,Francisco Javier De La Mata,José Luis Jiménez,Mª. Ángeles Muñoz-Fernández
Nanomedicine: Nanotechnology, Biology and Medicine. 2015; 11(6): 1481
[Pubmed] | [DOI]
209 Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy
Simeon K. Adesina,Emmanuel O. Akala
Molecular Pharmaceutics. 2015; 12(12): 4175
[Pubmed] | [DOI]
210 Oral Bioavailability: Issues and Solutions via Nanoformulations
Kamla Pathak,Smita Raghuvanshi
Clinical Pharmacokinetics. 2015; 54(4): 325
[Pubmed] | [DOI]
211 Enhancing photodynamic therapy of refractory solid cancers: Combining second-generation photosensitizers with multi-targeted liposomal delivery
Ruud Weijer,Mans Broekgaarden,Milan Kos,Remko van Vught,Erik A.J. Rauws,Eefjan Breukink,Thomas M. van Gulik,Gert Storm,Michal Heger
Journal of Photochemistry and Photobiology C: Photochemistry Reviews. 2015; 23: 103
[Pubmed] | [DOI]
212 Supramolecular nanoscale assemblies for cancer diagnosis and therapy
Sílvia Castro Coelho,Maria Carmo Pereira,Asta Juzeniene,Petras Juzenas,Manuel A.N. Coelho
Journal of Controlled Release. 2015; 213: 152
[Pubmed] | [DOI]
213 Drug Carrier for Photodynamic Cancer Therapy
Tilahun Debele,Sydney Peng,Hsieh-Chih Tsai
International Journal of Molecular Sciences. 2015; 16(9): 22094
[Pubmed] | [DOI]
214 Designing Dendrimer and Miktoarm Polymer Based Multi-Tasking Nanocarriers for Efficient Medical Therapy
Anjali Sharma,Ashok Kakkar
Molecules. 2015; 20(9): 16987
[Pubmed] | [DOI]
215 Emerging therapeutic delivery capabilities and challenges utilizing enzyme/protein packaged bacterial vesicles
Nathan J Alves,Kendrick B Turner,Igor L Medintz,Scott A Walper
Therapeutic Delivery. 2015; 6(7): 873
[Pubmed] | [DOI]
216 Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances
Nishant S. Gandhi,Rakesh K. Tekade,Mahavir B. Chougule
Journal of Controlled Release. 2014;
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Technology Platforms
    Dendrimers for D...
    Dendrimers for G...
    Drug-Dendrimer I...
    Physicochemical ...
   Toxicity Issues
   Other Applications
   Acknowledgement
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed16070    
    Printed230    
    Emailed2    
    PDF Downloaded1059    
    Comments [Add]    
    Cited by others 216    

Recommend this journal